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The last decade witnessed the unprecedented popularity of smartphones in all 
aspects of our lives. Two categories of smartphone applications – Medical, and Health 
and Fitness - which are collectively called ‘mobile health apps’ or mHealth apps also 
became universal. Their availability and accessibility to patients make them a 
potentially prescribable non-drug intervention to enhance self-management of many 
conditions. However, their effectiveness and usability are not well scrutinized. It is 
challenging for doctors to navigate 350 000 mHealth apps to find the right ones to 
recommend. Moreover, mHealth app use by Australian general practitioners (GPs) 
and the barriers and facilitators they encounter when integrating mHealth apps in 
their clinical practice have not been studied comprehensively. Potential solutions to 
overcome the barriers to prescribing effective mHealth apps in practice needs to be 
explored. 
Aims 
The overall aim of this thesis is to explore the possibility of better mHealth app 
prescription in Australian general practice. To achieve this aim, the three main 
research areas examined were: (1) the evidence of effectiveness of mHealth apps; (2) 
the barriers and facilitators to prescribing mHealth apps in Australian general 
practice; and (3) the feasibility of an intervention to increase app prescription by GPs. 
Methods and Results 
The aims were addressed by four interrelated studies. First, an overview of systematic 
reviews of randomized controlled trials (RCTs) of stand-alone mHealth apps 
evaluated the evidence-base behind “prescribable” apps. Prescribable apps were 
defined as: currently available, proven effective and preferably stand-alone. The 
overview identified 6 systematic reviews including 23 RCTs evaluating 22 available 
apps that mostly addressed diabetes, mental health, and obesity. Most trials were 
pilots with small sample size and of short duration. Risk of bias of the included 
reviews and trials was high. Eleven of the 23 trials showed a meaningful effect on 
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health or surrogate outcomes attributable to apps, thus qualifying the tested apps to 
be prescribable. 
Second, semi-structured interviews with GPs and patients were conducted to explore 
their perspectives on barriers and facilitators to mHealth app prescription in general 
practice. A total of 20 GPs and 15 adult patients (18-75 years old) were interviewed. 
From the GPs’ perspectives, the main barriers to prescribing apps were: a 
generational difference in the digital propensity for both the GPs and patients; lack of 
knowledge of prescribable apps and lack of reliable source to access them; time 
commitments required of the GPs and patients; and privacy, safety and 
trustworthiness of health apps. From the patients’ perspectives, the biggest barriers 
were the patients’ age and the usability of apps. Surprisingly, patients were not 
concerned about privacy and data safety issues. The facilitators of app prescription 
were similar for patients and GPs: (1) ubiquity of smartphones and apps and younger 
generation; and (2) trustworthy source of prescribable apps – for patients it was their 
doctors, but the doctors needed a reliable professionally vetted source to access 
effective apps. Evidence of effectiveness was identified as an independent theme by 
both GPs’ and patients.   
Third, a survey of Australian GPs aimed to assess how the barriers identified in the 
previous study were perceived in a national sample of GPs. Based on the findings of 
the second study, we developed specific questions to the mHealth section of the 2017 
Royal Australian College of General Practitioners (RACGP) Annual Technology survey. 
The survey gathered a total of 1014 responses, of which 621 completed the mHealth 
section. The participants’ median years practised was 20.7 years. Two-thirds of the 
GPs use apps professionally as medical calculators and point-of-care references. A 
little over half of the GPs recommended apps for patients daily, weekly or monthly 
(13%, 26%, and 13% respectively). Mindfulness and mental health apps were 
recommended most often (n=337; 33%), followed by diet and nutrition (n=144; 14%), 
exercise and fitness (n=132; 13%), and women’s health (n=104; 10%) related apps. 
Knowledge and usage of evidence-based apps from the Handbook of Non-Drug 
Interventions (HANDI) were low. The prevailing barriers to app prescription were 
lack of knowledge of effective apps (n=372; 60%) and lack of trustworthy source to 
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access them (n=96; 15%). GPs expressed their need for a list of safe and effective apps 
from a trustworthy source such as the RACGP. They prefer online video training 
material or webinar to learn more about mHealth apps.  
Lastly, a single group before-and-after study was conducted to evaluate the feasibility 
of app prescription in Australian general practice and to measure the effectiveness of 
an intervention to increase app prescription uptake. A two-part intervention was 
developed: a 6 app prescription pad and short introductory videos for each app. Of 
the 40 GPs recruited from all around Australia, 36 completed the study. Over 4 
months in total, 1324 app prescriptions were dispensed. The median number of apps 
prescribed per GP was 30 [range 6-111]. The median number of apps prescribed per 
GP per fortnight increased from the pre-study level of 1.7 to 4.1. Confidence about 
prescribing apps doubled from a mean of 2 (not so confident) to 4 (very confident). 
App videos did not affect subsequent prescription rates substantially. Post-study 
interviews revealed that the intervention was highly acceptable. 
Conclusions and implications 
The findings of these studies highlight the less than robust evidence-base for mHealth 
apps including major gaps in the quantity and the quality of the testing. We also 
identified that mHealth app prescription to be feasible in general practice both from 
the GPs’ and patients’ perspectives. Most GPs are using apps professionally and 
already recommend apps to patients, albeit sparingly. But their main challenges are 
lack of knowledge of effective apps and lack of trustworthy source to access them. A 
curated compilation of effective mHealth apps provided by a trustworthy professional 
organization would address both barriers. Our final study proved the feasibility of 
such solution in increasing app prescription. Besides creation and maintenance, the 
future of greater uptake of mHealth app prescription depends on the scalability and 
sustainability of a reliable app repository. 
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Before you become too entranced with gorgeous gadgets and 
mesmerizing video displays, let me remind you that information 
is not knowledge, knowledge is not wisdom, and wisdom is not 
foresight. Each grows out of the other, and we need them all.   






When Alexander Graham Bell invented the first telephone, little did he know that a 
century and a half later its infinitely smarter descendent would have inspired a new 
field in medicine called mobile health (mHealth). Nothing else parallels the 
explosive evolution that the telephone has gone through to become the most widely 
used piece of technology today - the smartphone. Integrated with another 
revolutionary invention, the internet, smartphones have made the accessibility of 
information, including health information extremely easy and more democratic than 
ever. 
A smartphone is a mobile phone that performs many of the functions of a computer 
with a touchscreen interface, internet access, and an operating system capable of 
running downloaded applications (apps). The penetration of smartphones globally 
has been phenomenal. The number of smartphones worldwide is predicted to reach 
5.8 billion by 2020, an increase which will be primarily driven by developing 
countries [1]. The unprecedented mobile computing power and the use of easily 
modifiable multimedia apps are what gives smartphones a unique advantage over 
other types of information and communication technologies, making them a vital 
part of mHealth.  
An “app” is the default abbreviation for smartphone software applications; app 
became a word in its own right in 2010 [2]. Apps are sold or offered for free in 
centralized digital market places such as App Store for Apple iOS devices and Google 
Play for Android devices. Between them, they own 96% of the smartphone market 
and 80% of the corresponding app markets [3]. Since their inception in 2008, the 
stores now offer more than 3 million apps each with download counts and revenues 
in the billions [4]. However, the download numbers are skewed; dominated by fewer 
than 5,000 apps, which account for 90% of the total downloads. The word “app” is 
also gaining traction as the preferred terminology over “software application” for 
literature search for studies that used smartphone apps [5].  
App stores have two app categories that concern medicine: Medical (related to 
specific conditions such as diabetes and depression), and Health and Fitness 
(wellness, diet, and exercise-oriented). Together they account for about 5% of all 
app downloads, which is a small proportion compared to the 25% of the most 
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popular category of Games [6]. The phrase “mHealth apps” covers both these 
categories of apps, thus will be used throughout this thesis. The latest market 
analysis reports that out of more than two million apps in the app stores, 350 000 
are mHealth apps [3]. However, the categorization at the app store is not perfect. A 
report by the IMS Institute for Healthcare Informatics found that only half of the 
mHealth apps in App store were genuinely health-related [7]. Regardless, over 
100,000 mHealth apps are still more than enough to cover all aspects of health and 
medical conditions.  
New terminologies and concepts arise with the creation and adoption of new 
paradigms. Laxminarayan and Istepanian were first to define mobile health in 2000 
as ‘unwired e-med’, signifying the mobility and wireless-ness of it over e-medicine 
or eHealth [8]. Mobile health is the practice of medicine and healthcare supported 
by mobile technology and devices. Because modern mobile devices use the internet 
to be fully functional, mHealth also fits under the area of electronic health (eHealth), 
which in turn encompasses virtually everything related to computers, the internet 
and medicine. Additionally, terms such as ‘digital health’ and ‘ubiquitous health’ 
(uHealth) are used commonly to cover eHealth, mHealth, and other interrelated 
concepts. It is challenging to clearly define solid borders around and between these 
new areas as there are many overlaps that keep changing with the technology. An 





Figure 1. The interrelationship between eHealth, mHealth and some of their components. 
mHealth offers many novel and ‘mobile’ ways to carry out eHealth and telemedicine 
through mobile internet, new and improved short message service (SMS), and other 
multimedia apps. Other digital innovations, such as wearable sensor technologies 
dubbed ‘wearables’ or ‘app-cessories’ that work with the associated apps are also 
an expanding area of mHealth.  
Application and benefit of mHealth apps in healthcare, and particularly in the 
general practice setting, is an intriguing area of research. mHealth apps have the 
potential to equip an unprecedented number of patients with tools to manage their 
health and well-being. However, better use of mHealth apps into clinical practice is 
challenged by the largely unregulated app industry, lack of well-established quality 
and safety standards, unclear evidence of effectiveness of mHealth apps, poor 
interoperability with existing medical systems, and a lack of comprehensive and 





The overall aim of this thesis was to evaluate the evidence of effectiveness of patient-
facing stand-alone mHealth apps and to explore the interest and feasibility of 
mHealth app prescription in Australian general practice. To achieve this, the studies 
comprising this thesis aimed to assess the evidence of effectiveness of mHealth apps, 
determine barriers and facilitators to prescribing mHealth apps in Australian 
general practice, and evaluate the feasibility of an implementation intervention to 
overcome the identified barriers to increase app prescription by GPs. 
1.3 RESEARCH QUESTIONS 
To achieve the aim, 8 research questions were addressed with four independent but 
interrelated studies (Figure 2).  
Study 1: Prescribable mHealth apps identified from an overview of systematic 
reviews 
1. Of the currently available smartphone health apps, how many have been 
rigorously tested and shown to be effective? 
2. How well have they been tested? What are the gaps in the research?  
Study 2: Barriers and facilitators to using mHealth apps in Australian general 
practice: a qualitative study 
1. What are the potential barriers to prescribing apps in general practice 
settings perceived by GPs and patients? 
2. What are the potential facilitators to prescribing apps in general practice 
settings perceived by GPs and patients? 
Study 3: Current knowledge and adoption of mHealth apps among Australian 
general practitioners: a survey study 
1. What are the knowledge, and use of health apps by Australian GPs? 
2. How do the barriers and facilitators to health app prescription that were 
identified during the interviews (study 2) reflect in a wider sample of GPs? 
Study 4: mHealth app prescription in Australian general practice: a feasibility study 
6 
 
1. Can the barriers to app uptake identified during Project 2 and 3 be overcome 
by an intervention?  
2. How effective is the intervention at increasing the uptake of app 
prescription by the selected cohort of GPs? 
 
Figure 2. Interrelationship between the studies planned to be conducted in this thesis 
1.4 OUTLINE OF THE THESIS 
The first chapter introduces the concepts and terminologies that will be used in this 
thesis along with the overall outline. Chapter 2 offers a review of the literature on 
mHealth apps, the effectiveness testing, main areas of application, and their usability 
in general practice setting. Chapter 3 reports Study 1, which addressed the first two 
research questions in an overview of systematic reviews of randomized controlled 
trials (RCTs) of mHealth apps. Chapter 4 describes Study 2, which explored the 
perspectives of GPs and patients towards mHealth app use in general practice. The 
barriers and facilitators observed in this study were used to inform subsequent 
studies in this thesis.  
Chapter 5 reports Study 3, which was a national survey of GPs that measured the 
current knowledge and adoption of mHealth apps among GPs and to validate the 
findings of the preceding qualitative study. Chapter 6 describes Study 4, which 
describes the pilot testing of the feasibility of an implementation intervention 
focused on increasing mHealth app prescription in Australian general practice.  
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Chapter 7 is a Discussion chapter, which brings together the findings and 
conclusions from the individual studies and presents an overall discussion about 
mHealth apps in a broader context. Recommendations for future research and other 
outstanding issues around mHealth app usability are provided.  
Note: The manuscript of study 1 and 3 are published and have been reproduced in 
compliance with the Creative Commons Attribution licence 4.0 and reformatted to 
be consistent with the rest of the thesis for improved readability. Manuscripts of 
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Chapter 2: Literature Review 
 
 
The key is to have humility about our innovations, and put 
them to rigorous testing. We can then progress by finding the 
occasional incremental advance, and the even rarer 
breakthrough. 




2.1 CURRENT EVIDENCE OF MHEALTH APP EFFECTIVENESS 
Despite the explosion in the number of mHealth apps, or perhaps because of it, the 
scientific literature is lagging behind. The exponential increase in the number of 
apps seems to command unquestioning acceptance of them into all aspects of life. 
However, for mHealth apps to be used as health interventions, a solid evidence base 
should be established first. Although many reviews analysed the content of mHealth 
apps from different fields, few reviews evaluate the effectiveness of apps by 
intervention studies.   
There is an overall trend that more apps are being developed to address chronic 
conditions such as diabetes and obesity (Figure 3). The global burden of these 
diseases is posing an imminent threat to population health and they are highly 
lifestyle-related, hence largely preventable [1]. The latest estimates of diabetes 
prevalence from the International Diabetes Federation show that the 382 million 
people with diabetes in 2013 will rise to 592 million by 2035 [2]. Nearly two billion 
adults worldwide were overweight and obese (BMI>25 and 30kg/m2 respectively) 
in 2014 [3]. Obesity and diabetes are two areas where smartphone health apps 
might offer a convenient and cost-effective way to promote and reinforce behaviour 
change.  
What smartphones and apps are offering is not an unforeseen phenomenon, but the 
result of natural evolution and progress of technological modalities that deliver 
tried and tested medical information and interventions to assist self-management. 
For the longest time, the most common approach for information dissemination for 
patients was printed educational materials [4].  The late 90s and early 2000s saw a 
few new approaches such as interactive CDs and DVDs and personal digital 
assistants (PDAs) [5, 6], only to be replaced by the arrival of smartphones. In 
contrast, web-based and SMS-based communications continue to survive, adapt to 
and evolve with the smartphones and apps [7-9]. The advanced and unique 
capacities of smartphones and mHealth apps such as the personalizability, 
interactivity, and mobility further enhance the convenience and the impact on 




comparison group [18-20]. A 0.5% reduction in HbA1c is borderline clinically 
significant and comparable to first-line pharmaceutical treatment [21]. However, to 
fully evaluate clinical significance and meaningfulness, other measures such as 
patients’ self-management skills, knowledge, and quality of life should also be 
considered. Heterogeneity is an issue in these meta-analyses due to differences in 
components of interventions, lengths, and baseline measurements. Overall, the 
higher the baseline level of HbA1c and the longer the intervention, the better the 
patient outcomes [17].  
Two primary studies report substantial decreases in HbA1c level but have problems 
with acceptability [22, 23]. The first trial tested a freely available stand-alone app 
called Glucose Buddy in type 1 diabetes patients. The intervention group had HbA1c 
decrease of 1.28% from baseline at 9-month follow up [22]. Glucose Buddy is no 
longer free of charge, as it has been acquired by an American company and the full 
functionality is available only by subscription. The second study tested the 
prototype of Blue Star app in type 2 diabetes patients. The intervention group’s 
HbA1c level decreased by 2.03% compared to 0.68% for the control group patients 
[23]. Blue Star became the first app to receive Food and Drug Administration (FDA) 
clearance in the US. However, it is not a stand-alone app and failed to demonstrate 
the same level of effectiveness when tested in Canadian primary care [24].  
WEIGHT LOSS 
The second most common area for mHealth apps is weight-loss and physical activity.     
Content analysis studies provide some idea of already available apps in the app 
stores and their quality. Because medical professionals and content experts are 
rarely involved in creating apps, they are currently designed with an emphasis on 
appearance over substance. A review of 379 physical activity apps found none of the 
apps adhered to evidence-based guidelines for aerobic physical activity [25]. 
Another review evaluated the most popular commercial apps for weight 
management [26] according to the Mobile App Rating Scale (MARS) devised by 
Stoyanov et al [27]. The 23 apps they investigated scored high in “functionality” with 
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an average MARS score of 4 out of 5, but scored low in “information quality” domain 
with an average MARS score of 2 out of 5.  
As for effectiveness, pooling studies together is challenged by heterogeneity in the 
interventions and the outcomes. A systematic review by Flores-Mateo et al provided 
three ‘forest’ plots to examine the effectiveness of app interventions on three 
outcomes: weight loss, body mass index (BMI) and physical activity [28]. According 
to this review, the app intervention groups lost 1kg more (BMI -0.43) than the 
control groups, which were comparable to SMS based weight loss studies [29]. 
However, the clinical significance of 1kg extra weight loss is minimal. Changes in 
weight and BMI can be compared or pooled together easily, but different measures 
of physical activity interventions need an extensive conversion of units to be 
compared. However, Flores-Mateo et al failed to provide any explanation on how 
they were able to compare step counts with vigorous physical activity, hence their 
analysis of app effect on physical activity was deemed inconclusive.  
For weight loss solely, two individual RCTs demonstrate both statistically and 
clinically significant results. The first one is MyMealMate app that helps make a daily 
recording of food and calories intake easier and more accurate [30]. It contains 
information on 23,000 food items that are sold in the United Kingdom (UK). The app 
intervention group lost 4.6kg over six months compared to paper diary (-2.9kg) and 
website (-0.5kg) groups.  The second trial compared a diet and exercise tracking app 
called Lose-It! with the app paired with intensive counselling (weekly), less-
intensive (monthly) counselling, and purely intensive counselling group with no app 
[31]. All groups lost weight, but the app paired with intensive counselling group lost 
3 times more weight (-5.4kg) than the app alone group (-1.8kg). Weight loss 
equivalent to 2-5% of the initial weight is considered clinically meaningful [32].  
In contrast, the most popular health and fitness app from the app stores called 
MyFitnessPal did not demonstrate any benefit when tested against a control group 
that was free to use any weight loss activity they choose [33]. MyFitnessPal is similar 
to Lose-It! and tracks diet and exercise. It has over 3 million food items in the 
database plus a barcode scanning function. The participants received no other 
intervention and were weighed at baseline, 3 and 6 months. However, at the end of 
the trial, there was no difference in weight loss between the groups. The study also 
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examined the app usage data of the participants, which decreased to zero towards 
the end of the trial.  
Step count can be a simple and more direct way to measure physical activity levels, 
for both patients and researchers [34]. An explosion in wearable technology in 
recent years has made 10,000 steps a day a ubiquitous target. The term was born 
when a pedometer manufacturer nicknamed the pedometer “manpo-kei”, a 
Japanese phrase for “10,000 steps meter” in the early 1960s. However, it is not 
entirely arbitrary. Japanese researcher Yoshiro Hatano studied walking habits in the 
following years and established the first classifications of step-related activity levels 
and energy expenditure, which have been validated globally since [35]. Fewer than 
5,000 steps a day is considered ‘sedentary’, and 10,000-13,000 means ‘active’. 
Perhaps a better interpretation would be to know that 10,000 steps roughly equals 
walking 8 kilometres, which takes about an hour and forty minutes, burning 
approximately 300 kcal for an average person. Since baseline activity levels and 
measuring device accuracy vary, it is important to establish individual starting 
points and increase it in achievable increments.  
A study in Ireland showed a smartphone pedometer app increased daily step counts 
by 2,017 more than the control group over 8 weeks in a primary care setting, which 
is equal to walking 1 mile [36]. However, long-term adherence and clinically 
meaningful outcomes are unknown because of the short duration of the trial. The 
participants reported that carrying their phones at all times was a practical 
challenge. Perhaps, commercial popularization of wearable trackers will help 
overcome this and improve long-term adherence. A recently published RCT 
reported that the baseline average step count of all participants was 9,670 steps a 
day and half of the participants already walked more than 10,000 steps a day [37]. 
However, considering the study goal was to increase daily activity to 10,000 steps a 
day, it is hard to see the benefit of 300 extra steps on the participants. Studies like 
this that have not been robustly designed or conducted can taint the reputation of 
mHealth and hinder its advances.  
Khaylis et al defined five key components of technology-based weight loss programs 
more than a decade ago: (1) self-monitoring, (2) counsellor feedback and 
communication, (3) social support, (4) structured program, and (5) individually 
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tailored program [38]. Weight-loss app studies commonly incorporate number 1, 3, 
and 4 but frequently exclude what evidence suggests to be the most important: 
professional feedback and individually tailored program. 
MENTAL HEALTH 
The number of mental health apps and app studies are rapidly increasing. Several 
systematic reviews and literature reviews have evaluated mHealth apps for 
conditions like depression, bipolar disorder, schizophrenia or mental health in 
general [39-42]. However, the quality of the app contents is shown to be poor or 
unsafe and the evidence of effectiveness to be small. An analysis of 117 depression 
apps chosen from the app store found that only 10% of those apps had a minimal 
level of content based on cognitive behavioural therapy (CBT) or behavioural 
activation (BA) and none had any efficacy/effectiveness studies behind them [43]. 
Another analysis showed the majority of 243 depression apps failed to mention 
their organizational affiliation and content source despite claiming their main 
purpose to provide therapeutic treatment and psychoeducation [44].  
One way to transition mental health into mHealth is to convert already proven web-
based psychotherapy interventions into smartphone apps [45-47]. Managing 
Depression app is one such example. Developed as one of 4 mental health apps under 
This way up project, it contains previously tested 12-week online CBT program for 
depression [45]. The app version has demonstrated to be equally effective as the 
web version, which was initially shown to decrease depressive symptoms compared 
to a waitlist control group (moderate to large effect size (Cohen’s d 0.63-0.89)). It is 
important to note that although the program can be used independently, both 
studies had psychologist support in forms of weekly emails or phone calls in 
addition to the interventions. The impact of such additional support and whether 
the same level of follow up and support is feasible in general practice setting 
remains to be seen. 
Studies of bipolar disorder and schizophrenia apps have been less successful. A 
review of 82 apps for bipolar disorder found 35 of these were symptom monitoring 
tools while another 32 provided information, but only covered 4 out of 11 core 
psychoeducation principles and 2 out of 13 best-practice guidelines [48]. A 
systematic review by Faurholt-Jepsen et al identified two research groups who are 
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testing smartphone-based self-monitoring apps for bipolar disorder [41]. However, 
these studies are yet to yield encouraging results. A 2015 review of smartphone 
apps for schizophrenia found only five small feasibility studies from research groups 
working on apps [40]. Only one of these was developed further and tested in an RCT 
[49]. Symptom monitoring is an important management strategy for chronic 
conditions and smartphones are well placed to be the medium that enables shared 
decision making, real-time feedback, ecological momentary assessment and 
ecological momentary intervention. 
CHALLENGES OF EFFECTIVENESS TESTING 
Some researchers have suggested that RCTs are not necessary or suitable to 
evaluate all mHealth interventions because the average time it takes for an RCT (2 
years) is far too long to evaluate fast-evolving technology-based interventions [50]. 
The challenge of ever-changing operating systems and long-term funding to upkeep 
the apps support the above argument. However, the effect of app interventions 
could be marginal, and small benefits can only be reliably detected by rigorous 
testing. Thus, RCTs should remain as the gold standard [51].  
Evidence for the effectiveness of smartphone mHealth apps seems to be small and 
scarce at the moment. Many pilot studies are just designed inadequately: the 
population size is too small, the intervention too complex, and duration too short 
and even fewer studies progress on to full-scale RCTs. To quote my supervisor Paul 
Glasziou “the key is to have humility about our innovations and put them to rigorous 
testing. We can then progress by finding the occasional incremental advance, and 
the even rarer breakthrough” [52].  
2.2 USABILITY OF MHEALTH APPS IN GENERAL PRACTICE 
General practice is a major part of the frontline of healthcare – primary care. GPs see 
hundreds of different conditions and patients of all ages and life stages. mHealth 
apps have the potential to benefit both doctors and patients in areas such as 
continuity of care, shared decision making, and the prevention and management of 
chronic conditions [53]. This section examines a number of app studies that have 
been conducted in general practice or primary care, which includes allied health and 
community pharmacy in addition to general practice and explore the usability of 
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mHealth apps in such settings. Although ‘general practice’ and ‘primary care’ are 
often used interchangeably, general practice is the setting of focus throughout the 
studies conducted for this thesis.   
As mentioned previously, diabetes, mental health and weight-loss apps make up the 
majority of the mHealth apps currently. Patients with diabetes and depression are 
two of the top ten most common conditions GPs consult with [54]. It is notable that 
weight loss inquiries are not in the top ten, or in fact in the top thirty most common 
GP consultations. The availability and variety of weight-loss interventions as a 
separate industry outside the medical establishment means that individuals can 
seek such interventions independently from their doctors’ advice, or doctors may 
not readily initiate the weight discussions due to consultation time constraints.  
STUDIES CONDUCTED IN GENERAL PRACTICE/PRIMARY CARE 
There are several studies of mHealth apps that have been conducted in primary care 
settings. A systematic review of 16 RCTs that tested technology-assisted weight-loss 
interventions in primary care concluded that the addition of technology helped to 
achieve significant weight loss (5-45% of patients lost 5 or more per cent of their 
initial weight) by incorporating already proven behaviour change elements such as 
self-monitoring, in-person feedback and targeted, structured lifestyle coaching [55]. 
More than half of the included studies lasted at least one year and about half of the 
studies had face-to-face follow-ups and physician consultations as part of the 
intervention. Both of these correlated with increased weight loss compared to fully 
automated interventions. Although the interventions included in this review were 
mostly web-based, it is an encouraging result of successful technology-based 
intervention in primary care in contrast to some short-term fully automated studies 
that did not produce tangible results that we discussed earlier [33, 36].  
However, there are other large RCTs that were conducted in real-world primary 
care/general practice settings that failed to demonstrate any benefit of using 
mHealth apps over the control group. One study used an app as an adherence 
support tool for increasing physical activity and the Mediterranean diet over 12 
months [56]. The control group received the same initial consultation and a leaflet 
instead of the intervention app. There were no between-group differences in the 
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outcomes at 3 and 12 months. The famed diabetes app BlueStar, which is the first-
ever FDA-approved app therapeutic in the US was shown to reduce glycated 
haemoglobin HbA1c levels by 1-2% in the initial studies [23, 57, 58] but failed to 
show the same level of effectiveness when tested in Canadian primary care setting 
in a pragmatic RCT [24]. This highlights the importance of testing mHealth apps in 
real-world settings before branding them as effective.  
General practice consultation is also an important opportunity to address common 
modifiable risk factors such as smoking and hazardous drinking. In general, text 
message-based smoking cessation interventions have been shown to improve 
adherence to quitting and long-term abstinence by 67% [59, 60]. However, 
implementation of SMS programs in general practice would require additional 
human and technical resources, unlike stand-alone smoking cessation apps that 
patients can download directly onto their smartphones.  
A Cochrane review of smoking cessation apps showed that there was low-level 
evidence that cessation apps were as effective as traditional low-intensity support 
[61]. However, a review of 112 cessation apps available in Australia found only two 
of them were evaluated for their efficacy [62]. Individual studies of cessation apps 
show apps with advanced content such as the incorporation of acceptance and 
commitment therapy (ACT) or cognitive behavioural therapy (CBT) were more 
effective than simpler information-based apps [63, 64]. An Australian cessation app 
that provided decision aid with additional structured support such as motivational 
messages, quitting diary and benefits tracker, was twice as effective as an 
information-only app at 3 months (RR 2.08, 95% CI 1.38-3.18) [65]. Unfortunately, 
this app is no longer available due to a lack of ongoing funding to update and 
maintain it.  
There is a scarcity of mHealth apps that address harmful alcohol use except for blood 
alcohol concentration (BAC) calculating apps [66]. A Swedish study tested a 
government-backed mobile BAC app among university students [67]. Not only the 
attrition rate was high (40%), the results showed increased drinking among 
participants over the seven weeks. The researchers provided explanations such as 
the heaviest drinking holidays happened during the study and the students were 
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able to drink more because the app did not display BAC over 0.08%, which is the 
legal limit for driving, therefore, giving a false sense of reassurance. Such backfiring 
could have dangerous implications; hence more careful intervention design is 
needed. Another app designed to support abstinence for people who are leaving 
residential alcohol treatment was evaluated in an RCT and found that the 
intervention helped people to achieve an extra one and a half alcohol-free day per 
month compared to people with no such support [68]. The clinical significance of 
this result is minimal and alcohol use curbing remains an underutilized area of app 
development.  
PATIENTS’ PERSPECTIVES 
Patients are the end-users of mHealth apps, therefore their values, needs and 
preferences should be taken into account during app development and testing. 
Smartphone ownership is increasing every year and Australia is among the leaders 
in the world around 90% [69]. mHealth apps download counts are in the billions, 
however, most apps were used only a few times [70]. A large survey found that 
younger educated female cohort was more likely to use mHealth apps and consume 
more fruit and vegetables, and exercise more than people without smartphones or 
mHealth apps [71].  
In contrast, patients with multiple chronic conditions reported that they would like 
to use mHealth apps and technology to track their life and health more but tracking 
feels like a job and can evoke negative emotions like being reminded that they are 
“a sick person” or “a bad patient” [72]. They also felt that their tracking data were 
not trusted or valued by their doctors who preferred lab reports. This highlights the 
importance of education and communication about the use of new technology and 
patient-generated data in healthcare.   
Still, there are examples of mHealth apps potential to trigger and support positive 
behaviour change among patients. Patients reported that participation in a 
pedometer app study not only helped change their relationship with exercise but 
also had “sequential and synergistic positive cascade effect” (pp e503) [73]. The 
researchers termed it the “Know-Check-Move” effect and illustrated the relationship 
between the identified themes (Figure 4). Knowing the current state of their health 
helped patients visualize what is it that they need to work with or improve on, and 
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enabled them to check their status and progress, which encourages positive actions 
in managing health and medical conditions.   
 
Figure 4. The ‘Know-Check-Move’ effect. Patients from smartphone pedometer app study 
reported that their experience of these seven steps shown in the graph during the trial 
affected their attitudes and behaviours around exercise positively. (Casey M, Hayes PS, 
Glynn F, G OL, Heaney D, Murphy AW, et al. Patients' experiences of using a smartphone 
application to increase physical activity: the SMART MOVE qualitative study in primary 
care. The British journal of general practice : the journal of the Royal College of General 
Practitioners. 2014;64(625):e500-8 [73]). 
Studies increasingly show that the majority of patients are interested in using 
mHealth apps but mHealth apps can only help patients if the patients can find and 
access safe and effective apps to use [74, 75]. The overwhelming number of apps in 
the app stores makes it challenging and patients need trustworthy and reliable 
guidance or source to find the right apps [76]. A survey conducted by the Consumer 
Health Forum of Australia showed that GPs were the most trusted source of mHealth 
app recommendation ahead of government (5th place out of 9) with Google and App 
store coming in last [77]. This is a clear demonstration of the importance of 
equipping GPs and other primary care providers with proper information and 
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trustworthy guidance on mHealth apps so that they can provide the same to their 
patients.   
DOCTORS’ PERSPECTIVES 
American Medical Association (AMA) survey found more than a third of the doctors 
have recommended mHealth apps to patients [78]. The AMA stated its support for 
the use of mHealth apps in clinical practice provided that the apps have high-quality 
evidence for safety and effectiveness and that the doctors adhere to evidence-based 
practice guidelines.  
In Australia, the Royal Australian College of General Practitioners (RACGP) has been 
surveying GPs’ knowledge and use of technology and mHealth apps annually since 
2015[79, 80]. Australian GPs’ use of apps has increased from 40% in 2016 to 60% 
in 2018, which is thrice as much as French GPs’ [81]. GPs with up to 20 years of 
experience are more comfortable with new technology compared to older GPs. The 
most common areas of apps they recommend have been mental health, fitness and 
nutrition, and women’s health. Barriers to using technology more in their daily 
practice included lack of perceived needs and benefits, lack of knowledge and 
training on proper use of the new technology, and lack of practice incentives. 
Doctors have also expressed their concerns around data safety, interoperability and 
increased workload when adopting new technology into their practice. A recent 
review identified almost 180 factors that influence mHealth adoption such as cost, 
risk-benefit analysis, and ease-of-use in addition to the above concerns [82]. 
However, successful uptake of Health intervention will require identification of 
more specific barriers to the location and healthcare setting.   
Despite the barriers and concerns, there has been growing efforts to facilitate official 
“app recommendation” or “app prescription” around the world. In America, private 
initiatives that offer a repository of mHealth apps such as AppScript, RxUniverse, 
and iMedicalApps have been popping up [83]. However, such initiatives have been 
mostly set up by health tech companies and curated by early-adopters in healthcare 
who are excited about the possibilities of mHealth apps, thus can be fallible to 
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potential bias, conflict of interest, and to the issue of expert curation replacing 
evidence-base [84].  
The UK set up a more official system, where the National Health Service (NHS) 
Digital Health Choices initiative took the leadership to compile safe and 
recommendable apps for doctors and patients [85]. In 2019, the National Institute 
for Health and Care Excellence (NICE) released “Evidence Standards Framework for 
Digital Health Technologies” to help streamline the app quality assurance in the UK 
[86]. It outlines three tiers of evidence required according to the functions of the 
apps and tier three is required for mHealth apps that diagnose, monitor, calculate, 
treat health and medical conditions. The NHS App library outsources the evaluation 
of mHealth apps to two private companies [87, 88].  
Another approach to support app prescription is to equip doctors with a framework 
to evaluate apps themselves. The American Psychiatric Association (APA) pioneered 
the work in this area and released its first framework for doctors in 2017[89]. Since 
then they have expanded it to include important subcategories in each step of 
evaluation (Figure 5) [90]. This is a hierarchical pyramid model, which means the 
privacy and security are evaluated before the evidence base and therefore more 
important in deciding whether the app is good enough for clinical use. Some would 
argue that the evidence should be more important, i.e. moved ‘down’ on the 
hierarchy or precede the security concerns, because if there is no evidence of benefit 
of the apps, then no matter how secure their data storage is, the app will be of no 
use to patients. Perhaps a model where these five levels of evaluation are organized 





Figure 5. The American Psychiatric Association guideline for app evaluation. (Henson P, 
David G, Albright K, Torous J. Deriving a practical framework for the evaluation of health 
apps. The Lancet Digital Health. 2019;1(2):e52-e4. [90]). 
It may not be feasible or sustainable to ask time-poor GPs to take on the 
responsibility to find safe, effective and usable mHealth apps themselves. The key to 
successful mHealth app prescribing in primary care is not to burden the patients 
and the doctors with additional infrastructure, human resources, and extensive 
learning, but to harness existing opportunities such as the patient’s own device and 
motivation, and the doctor’s knowledge of reliable mHealth apps. This bottom-up 
approach will minimise the initial hurdle of integration of mHealth into primary care, 
compared to top-down systemic changes in healthcare. The following chapters will 
detail the series of four studies we conducted to explore the feasibility of mHealth 
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In the previous chapters (chapter 1-2) we established the concepts and 
terminologies that will be used in this thesis, outlined the research questions and 
chapters, and presented a preliminary literature review that started to explore the 
research areas we focus on.  
In this chapter, we will answer the first two research questions to systematically 
evaluate the evidence base for prescribable mHealth apps and identify the research 
gaps in testing and reporting of mHealth apps. This chapter has been published 
under the title “Prescribable mHealth apps identified from an overview of 
systematic reviews” in npj Digital Medicine journal in May 2018.  
Work arising from this chapter has also been presented at the annual Higher Degree 
Research student conference at Bond University; Gold coast Health and Medical 
Research conference; and Australian Society for Medical Research annual scientific 






Background: Mobile health apps aimed at patients are an emerging field of mHealth. 
Their potential for improving self-management of chronic conditions is significant. 
Here, we propose a concept of “prescribable” mHealth apps, defined as apps that are 
currently available, proven effective, and preferably stand-alone, i.e., that do not 
require dedicated central servers and continuous monitoring by medical 
professionals.  
Objectives: To conduct an overview of systematic reviews to identify such apps, 
assess the evidence of their effectiveness, and to determine the gaps and limitations 
in mHealth app research.  
Methods: We searched four databases from 2008 onwards and the Journal of 
Medical Internet Research for systematic reviews of randomized controlled trials 
(RCTs) of stand-alone health apps.  
Results: We identified 6 systematic reviews including 23 RCTs evaluating 22 
available apps that mostly addressed diabetes, mental health and obesity. Most 
trials were pilots with small sample size and of short duration. Risk of bias of the 
included reviews and trials was high. Eleven of the 23 trials showed a meaningful 
effect on health or surrogate outcomes attributable to apps.  
Conclusion: We identified only a small number of currently available stand-alone 
apps that have been evaluated in RCTs. The overall low quality of the evidence of 
effectiveness greatly limits the prescribability of health apps. mHealth apps need to 
be evaluated by more robust RCTs that report between-group differences before 
becoming prescribable. Systematic reviews should incorporate sensitivity analysis 
of trials with high risk of bias to better summarize the evidence, and should adhere 




The number of smartphones worldwide is predicted to reach 5.8 billion by 2020 [1] 
and there are 6 million multimedia applications (apps) available for download in the 
app stores [2]. According to the latest report from IQVIA Institute for Human Data 
Sciences (formerly IMS Institute for Healthcare Informatics) 318,000 of these are 
mHealth apps [3]. As one of the prominent digital behaviour change interventions 
of our time, mHealth apps promise to improve health outcomes in a myriad of ways: 
by helping patients actively measure, monitor, and manage their health conditions 
[4].  
Here, we propose a concept of “prescribable” mHealth apps, defined as health apps 
that are currently available, proven effective, and preferably stand-alone. When 
proven effective and available, stand-alone mHealth apps that do not require 
dedicated central servers and additional human resources, can join other simple 
low-cost non-pharmaceutical interventions that can be “prescribed” by general 
practitioners (GPs).  
However, although there are a number of systematic and other reviews of mHealth 
apps aimed at particular health conditions that examined different aspects of the 
apps such as the contents, quality and usability [5-8], no overview of systematic 
reviews has been done yet to summarize the effectiveness of stand-alone mHealth 
apps specifically and across different health conditions that present in general 
practice. Overviews of reviews are an efficient way to gather the best available 
evidence in a single source to examine the evidence of effectiveness of interventions 
[9]. Hence, our objectives were to: (1) conduct an overview of systematic reviews of 
randomized controlled trials (RCTs) to identify and evaluate the effectiveness of 
prescribable mHealth apps; and (2) determine the gaps and limitations in mHealth 
app research.  
3.3 METHODS 
The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
reporting guideline and the Overview of Reviews chapter (Chapter 22) of the 
Cochrane Handbook of Systematic Reviews of Interventions Version 5.1.0 were used 






We searched four electronic databases for systematic reviews without language 
restrictions: Medline Ovid, Cochrane Database of Systematic reviews, EMBASE, and 
Web of Science from 1 January 2008 through 1 February 2017. The cut-off date of 
2008 was chosen as it coincides with the release of smartphones capable of running 
third-party Apps and when the two major App stores opened. We developed the 
initial search terms for Medline Ovid, and then modified for other databases. Our 
search terms included combinations, truncations, and synonyms of “cell phone”, 
“smartphone”, “application”, “intervention”, “patient”, “public”, “outcome”, 
“effectiveness”, “improvement”, “reduction”, “review” and “meta-analysis”. The full 
search strategy for all databases is provided as supplementary information 4.  
Searching Other Resources  
In addition to the search of electronic databases, we did forward and backward 
citation searches of included systematic reviews, and hand-searched the Journal of 
Medical Internet Research (JMIR) from inception. We also contacted the authors of 
potentially includable trials to ascertain the availabilities and the progress of the 
app interventions as it was often unclear whether the apps were released, 
discontinued, or still in testing with plans for release. Additionally, we contacted 
many authors of trials that used text messages, PDA apps and web-based 
interventions to find out if those interventions were developed into smartphone 
apps.   
Data Collection and Analysis 
Selection of Reviews:  
Two authors (OB, PG) screened titles and abstracts of the search results 
independently. We then retrieved in full text articles and one author (OB) assessed 
them according to the inclusion criteria outlined above with the second author (PG) 
assessing a random sample. Where the eligibility of the studies could not be 
determined due to insufficient information supplied in the abstract or absence of an 
abstract, the full text articles were obtained. Any disagreements between reviewers 
were resolved by discussion and consensus or by consulting with a third author (EB). 
When more than one publication of a study was found, the most recent and or the 
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most complete one was used for data analysis. Systematic reviews excluded after 
full text review are provided as supplementary materials 2 with reasons for 
exclusion.   
Data Extraction and Assessment of Risk of Bias 
Two authors (OB, SS) independently extracted the following data from the included 
systematic reviews using a form developed by the authors for this review: study ID 
(first author’s last name and publication year), study characteristics (population, 
intervention, comparator, outcome, study design) and limitations of the review. We 
also extracted data from the RCTs of currently available stand-alone health apps. 
Along with general study characteristics information, we presented information 
gathered via contacting the authors for the availability of the intervention apps and 
other practical issues regarding their prescribability. Two authors (OB, SS) assessed 
the risk of bias of the included systematic reviews according to Cochrane’s Risk of 
Bias in Systematic reviews (ROBIS) tool [12]. Any disparities were resolved by 
consulting with a third author (EB).  
3.4 RESULTS 
Search results 
The PRISMA flowchart of the study selection process is presented as Figure 6. Our 
electronic searches and the other sources search identified 981 publications. After 
deduplication, we screened 799 titles and abstracts, and assessed 145 full text 
articles for eligibility. One hundred and sixteen full text articles were excluded: 22 
did not qualify as systematic reviews, 40 studies used non-app intervention, 4 
studies were duplicates, 6 were abstracts only, 4 articles evaluated only the 
contents of the apps, and 40 studies did not meet one or more of the inclusion 
criteria (supplementary table 1). Of the twenty-nine articles eligible for inclusion, 
20 reviews were excluded because they covered the same app trials as 6 more 
recent systematic reviews that were included in our overview (supplementary 
table 2) and 3 reviews were excluded due to apps still being unavailable 




Figure 6. PRISMA flow diagram of selection of systematic reviews. 
*Table of excluded articles due to Inclusion and Exclusion criteria mismatch is provided as 
supplementary table 1. 
^Table of excluded articles due to repeated coverage is provided as supplementary table 2. 
To achieve our study objectives, we used available systematic reviews of RCTs as a 
source of stand-alone mHealth apps that have been evaluated. We then determined 
the availability of those apps to ascertain the prescribability by searching the app 
stores and by contacting the authors of the RCTs. Figure 7 illustrates the scope of 
our study. Due to lack of established data on each category, the circle sizes and 




Figure 7. Scope of the overview 
We contacted 144 authors to determine the type and availability of their study apps. 
A little over half of the authors replied and we were able to include 3 app RCTs in 
our analysis as a result. We also found out that 25 app projects were discontinued.  
Description of Included studies 
Six published systematic reviews met the inclusion criteria for this overview [13-
18]. Characteristics and the limitations of the included systematic reviews are 
presented in Table 2. The systematic reviews were published in 2015-2017 and 
included a total of 93 RCTs and 18 studies of other designs. However, only 23 of the 
RCTs evaluated currently available stand-alone health apps. Characteristics of these 
RCTs are shown in Table 3 along with information about their availability and 
prescribability.    
One of the systematic reviews addressed diabetes [13], two addressed mental health 
[14, 18], another two addressed physical activity and weight loss related issues [15, 
17], and one addressed all of these areas by addressing the behaviour change aspect 
of apps [16]. Four of the reviews also included meta-analyses [13-15, 18]. We 





Effects of Interventions 
DIABETES 
The Bonoto 2017 systematic review assessed app interventions for both types of 
diabetes mellitus [13]. It included 13 RCTs, of which 5 were relevant to this overview 
[19-23]. All of the RCTs aimed to improve glycemic control and quality of life as 
measured by multiple biochemical markers. The meta-analysis showed a mean 
difference of -0.4% (95% CI -0.6, -0.3) in glycated hemoglobin levels favoring the 
intervention. Four of the app trials were tested on type 1 diabetes patients, of which 
two demonstrated a significant between group reduction in HbA1c levels [20, 23]. 
One that was tested for type 2 diabetes patients did not show any between group 
differences in HbA1c levels at one year [22]. All the diabetes apps include functions 
to log blood glucose levels, insulin dose, diet and physical activity, and to set push 
notifications and reminders. Two of the apps also offer versions for doctors to enroll 
and monitor multiple patients [19, 21]. At this stage, only two of these diabetes apps 
are available free of charge worldwide [21, 23].  
MENTAL HEALTH 
The Firth 2017 systematic review assessed interventions aimed at reducing anxiety 
[14]. It included 9 RCTs, of which 2 were relevant to this overview. Their meta-
analysis of the effects of smartphone interventions on symptoms of anxiety found 
small-to-moderate positive effect favoring the intervention (Hedges’ g=0.3, 95% CI 
0.2, 0.5). 
Two of the RCTs from this review used stand-alone apps that were available. A 
breathing retraining game app called Flowy did not show any significant reduction 
in anxiety, panic, and hyperventilation [24]. The basic version of SuperBetter app 
was tested against its “fortified” version, which contains more cognitive behavioral 
therapy (CBT) and positive psychotherapy (PPT) content, and a waitlist control 
group [25]. Depression scores were equally reduced in both app groups compared 
to the control group, but the attrition rate was high (80%) in both app groups over 
four weeks.  
The Payne 2015 systematic review assessed app interventions for their behaviour 
change potential [16]. It included 14 RCTs and 9 feasibility and pilot studies, of 
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which 7 RCTs were eligible for our overview. Only one of the RCTs tested an app for 
depression against a previously validated web-based cognitive behaviour therapy 
(CBT) program [26]. Both groups had equally significant improvements. This app is 
now called Managing Depression as a part of 4 app series called This Way Up and 
available for AUD 59.99.  
Two other trials included in Payne 2015 systematic review explored use of mobile 
apps to curb alcohol use among university students [27] and patients leaving 
residential treatment for alcohol use disorder [28]. The results showed that alcohol 
use increased among university students who used the intervention app 
Promillekoll, which calculated blood alcohol concentration (BAC) up to the legal limit 
[27]. Whereas, the A-CHESS app that was designed to provide on-going support for 
people leaving alcohol rehabilitation was shown to lessen the risky drinking days in 
the previous 30 days with higher odds (OR 1.94, 95%CI 1.14-3.31, p=0.02) [28]. 
These apps are available in Sweden and the USA respectively. 
The Simblett 2017 systematic review assessed e-therapies aimed at treating 
posttraumatic stress disorder (PTSD) [18]. It included 39 RCTs. The meta-analysis 
showed standardized mean difference (SMD) of -0.4 (95% CI -0.5, -0.3) favoring the 
intervention, however the heterogeneity was high (I2=81), which was not explained 
by the subgroup and sensitivity analysis.  Only one of the RCTs tested an app called 
PTSD Coach against waitlist control for 1 month; however, there were no significant 
between group differences in the PTSD Checklist-Civilian questionnaire result [29].  
WEIGHT LOSS AND PHYSICAL ACTIVITY  
Two systematic reviews evaluated apps for weight loss and physical activity. The 
Flores-Mateo 2015 systematic review assessed studies aimed at increasing weight 
loss and physical activity for overweight and obese people of all ages [15]. It 
included 9 RCTs and 2 case control studies of which 5 RCTs were relevant to this 
overview. A meta-analysis of nine studies showed app interventions reduced weight 
by -1.0kg (95% CI -1.8, -0.3) more than the control group. Net change in body mass 
index (BMI) showed mean difference of -0.4 kg/m2 (95% CI -0.7, -0.1) favoring the 
intervention. Net change in physical activity resulted in standard mean difference of 
0.4 95% CI -0.1, 0.9), however, the heterogeneity was high (I2=93%) and the authors 
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did not explain why several RCTs that reported physical activity outcomes were 
excluded from this meta-analysis.  
Four of the RCTs from this review used calorie counting apps as interventions [30-
33]. However, only one of them (MyMealMate app) showed a statistically significant 
between-group difference in weight loss [31]. The MyMealMate app includes calorie 
information of 23,000 UK-specific brands of food items in the database, and goal-
setting, physical activity monitoring and automated text-messages functions. When 
compared against a self-monitoring slimming website, the app group lost notable 
amount of weight and BMI, but not compared to the control group that used a calorie 
counting paper diary. MyFitnessPal app is one of the consistently highest rated free 
apps for calorie monitoring and it contains database of 3 million food items. 
However, when tested on its own for 6 months, the intervention made almost no 
difference to the weight of the participants [32]. This study also provided an insight 
on the usage of the apps during the trial, which showed that the logins to the app 
dropped sharply to nearly zero after 1 month from acquiring it. These three studies 
also suffered from a high overall attrition rate of more than 30% and the 
intervention groups lost more participants than the control groups. Another calorie-
counting app FatSecret was tested as an addition to a weight-loss podcast made and 
previously proven effective by the same study team. The results showed no 
difference in weight loss between the groups [33].  
The Schoeppe 2016 systematic review assessed studies aimed at improving diet, 
physical activity and sedentary behavior [17]. It included 20 RCTs, 3 controlled trials 
and 4 pre-post studies, but only 8 RCTs were relevant to this overview. It 
synthesized the trials in tabular and narrative formats, and assessed the quality of 
the trials using the CONSORT checklist [34]. Two of the RCTs tested so-called 
“exergame” (gamified exercise) apps called Zombies! Run, The Walk, Get Running and 
an activity monitoring app MOVES [35, 36]. Both studies had very low attrition rates, 
but failed to demonstrate any significant between group differences in 
improvements in physical activity and its indicators and predictors such as 
cardiorespiratory fitness, enjoyment of exercise and motivation.  
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One trial assessed an app aimed at increasing vegetable consumption called 
Vegethon on a small sample of participants of a 12-month weight loss program [37]. 
People who used the app consumed adjusted mean difference of 7.4 more servings 
of vegetable per day than the control group at 12 weeks (95% CI 1.4-13.5; p=0.02). 
Another physical activity trial tested a tablet-based app ActiveLifestyle among 
independently living seniors [38, 39]. Between-groups comparisons revealed 
moderate effect for gait velocity (Mann-Whitney U=138.5; p=.03, effect size r=.33) 
and cadence (Mann-Whitney U=138.5, p=.03, effect size r=.34) during dual task 
walking at preferred speed in favor of the tablet groups.  
There were two apps that were tested in two different studies that were included in 
both the Flores-Mateo and Schoeppe systematic reviews. The Lose-It! app was tested 
for 6 months [30] and for 8 weeks [40]. Not only they did not find any between group 
differences in results, in the second study the app group lost less weight than the 
two control groups that used a paper diary and the memo function of the phone. In 
contrast, the AccupedoPro pedometer app demonstrated a similar amount of 












Our overview evaluated six systematic reviews that included 23 RCTs of 22 
currently available stand-alone health apps. Eleven of the 23 trials showed a 
meaningful effect on health or surrogate outcomes attributable to apps (Table 3). 
However, the overall evidence of effectiveness was of very low quality [43], which 
hinders the prescribability of those apps. Most of the app trials were pilot studies, 
which tested the feasibility of the interventions on small populations for short 
durations. Only one of the pilot trials has progressed on to a large clinical trial [20]. 
The most commonly trialed apps have been designed to address conditions with the 
biggest global health burden: diabetes, mental health, and obesity. Although there is 
widespread acceptance of smartphones and promise of health apps, the evidence 
presented here indicates few effectiveness trials of health apps. The risk of bias of 
both the included reviews and the primary studies is high. The reviews lacked 
sensitivity analyses to integrate the risk of bias results into context. Some of the 
RCTs also suffered from high attrition rates, sometimes in the intervention groups 
more than the controls [24, 25], thus compromising the positive results and the 
conclusions drawn from the studies.  
STRENGTHS 
Although we set out to do a traditional overview of systematic reviews, it quickly 
became apparent that in order to ascertain the availability of the stand-alone 
mHealth apps, which was crucial to our objectives, we needed to investigate the 
primary trials of the apps. We have provided a window into the body of evidence on 
currently available stand-alone mHealth apps with a special focus on the 
“prescribability” in general practice settings, because this is where effective stand-
alone apps can benefit both general practitioners and patients. It is also possible for 
other primary care practitioners, such as diabetes nurses and physiotherapists, to 
prescribe suitable health apps to patients.  
There are a number of previous overviews of systematic reviews in eHealth and 
mHealth areas that can be comparable to ours in scope and methodology [44-48]. 
Two of them used the Overview Quality Assessment Questionnaire (OQAQ) and the 
others used the AMSTAR tool to assess the quality of the included systematic 
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reviews [49, 50]. We chose to use Cochrane’s newly developed ROBIS tool, which 
focuses more on the risk of bias attributes and the quality of the methods compared 
to AMSTAR [51]. Also, we did not restrict our search to any one language as many of 
these overviews did. Overviews are often limited by the individual limitations of the 
included systematic reviews, lack of risk of bias assessments, and challenge of 
synthesizing the overall results, and ours is no exception [45, 46]. We sought to 
overcome these limitations by contacting an extensive list of primary study authors 
to fill in the gaps left by the systematic reviews, and by assessing the risk of bias of 
included reviews vigorously. Despite the differences, our findings echo the 
conclusions of all these overviews regarding low quality of evidence in mHealth and 
eHealth areas they investigated. However, the high heterogeneity of the investigated 
interventions ranging from text messages, web tools, phone calls to apps, makes 
their recommendations too general and broad. We aimed to make our study more 
useful by exclusively focusing on a specific type of mHealth intervention with a 
vision of practical application in general practice. 
LIMITATIONS 
Our review was limited by the weaknesses in the systematic reviews we identified. 
The systematic reviews did not thoroughly adhere to the PRISMA statement [10] by 
not assessing the included studies’ risk of bias or not integrating the risk of bias 
results into the overall synthesis, thus preventing the reader from recognizing the 
poor quality of the included studies. The lack of understanding of risk of bias 
assessment prevented the authors from addressing this limitation in their 
discussions, as was evident during our ROBIS assessment. In addition, our overview 
was unable to assess the RCTs of health apps published in the past year because they 
are yet to be included in any systematic reviews and we specifically aimed to 
synthesize only systematic reviews. This highlights the necessity of timely updates 
of high levels of evidence in this field, which is further discussed in the Implications 
for research section.  
Furthermore, information regarding app availability was often not available in the 
primary studies. Thus, to compile the information on practical issues in Table 3 and 
to determine the current availability of apps, we had to contact primary study 
authors and search in the app stores. This emphasizes the importance of providing 
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complete and transparent reporting of app interventions [52], as is true of other 
interventions in health care [53]. We believe that sharing information amongst 
researchers working in app development is vital to reduce research waste and 
prevent re-invention of wheels [54]. We also found several cases where, despite the 
initial trials failing to demonstrate any positive benefit, the apps were still released 
(Table 3), adding to the ‘noise’ rather than the ‘signal’ in this field, and leading to 
opportunity costs. In other cases, app testing and release were terminated due to 
lack of ongoing funding as the technology requires constant updates and 
improvements. Thus, it is important to secure a necessary funding source before 
engaging in an app development and testing efforts.      
IMPLICATIONS FOR PRACTICE 
At present, anyone can create and publish health and medical apps in the app stores 
without having to test them, and patients must experiment with apps by trial and 
error. If GPs are to prescribe health apps, then they must be confident that the apps 
are shown to work, have fair privacy and data safety policies, and usable at the very 
least. However, assessment of individual apps and literature searches on app 
evidence are highly time-consuming and challenging for doctors to do on their own. 
Hence, we suggest that an independent and reliable source to carry out the 
evaluation of apps and to provide a collection of trustworthy mHealth apps is vital 
in providing practicing doctors with prescribable apps.  
Recently re-opened NHS Apps library is a great example of such source of apps for 
doctors’ use despite their initial hurdles with data safety of some of the previously 
recommended apps [55]. They employ a tool to make app prescribing even easier 
by collaborating with AppScript app [56]. There have been numerous efforts around 
the world to provide quality and efficacy assessments of mHealth apps, each 
devising and using their own app evaluation framework. The challenges and the 
complexity of those efforts are well summarized by Torous et al [57]. Thus we 
believe initiatives like NHS App library is the safer and more accountable way to 
implement digital interventions in real practice. Like clinical guidelines, a 
recognized national body can decide what framework they want to use and which 
apps to deem safe for use in practice in that particular country.   
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IMPLICATIONS FOR RESEARCH 
Our overview found a number of methodological shortcomings in evaluation of 
mHealth apps. Consistent sources of high risk of bias in the primary RCTs were 
failure to blind participants and personnel to the intervention, and poor reporting 
of allocation concealment. Although blinding can be challenging in mHealth studies, 
it is important because of the digital placebo effect [58]. Creating and using a basic 
static app or sham app for the control groups can help account for digital placebo 
effect and help establish the true efficacy of the interventions. Allocation 
concealment in mHealth trials can be done in the same way as in any other RCT by 
employing personnel who do not have any contact with the participants to handle 
the app installations; however, hardly any RCTs tried to ensure this. Several studies 
also noted that the control groups were susceptible to contamination with apps 
using the same or similar interventions to the tested app, since there are thousands 
of apps freely available to them outside of the research setting [32, 59]. Without 
providing controlled smartphones to study participants, it is difficult to identify 
simple solution to this challenge. Lastly, the only way to establish the effect of an 
intervention is by demonstrating greater change in one group compared to the other, 
rather than comparing it to the baseline [60]. Yet, many RCTs did not adhere to the 
relevant guideline [34] and report their results as between-group differences. 
The value of RCTs to evaluate fast-evolving mHealth interventions has been 
challenged due to their long duration, high cost and rigid designs, and multitude of 
modifications and alternative methods have been suggested, but widespread 
consensus is yet to be reached [61-63]. As our overview showed that the effect of 
apps as health interventions might be marginal, and such small benefits can only be 
reliably detected by rigorous testing. Thus, RCTs should remain the gold standard, 
but should be employed with tact: only when the intervention is stable, can be 
implemented with high-fidelity, and has a high likelihood of clinically meaningful 
benefit [64].  
We also emphasize the value of traditional systematic and other reviews. The role 
of these higher levels of evidence is not only to assess and summarize the evidence 
of a field, but also to reveal the gaps and shortcomings in existing research, which 
our overview has done. If it finds that the base of the evidence pyramid is shaky, that 
52 
 
is the trials being done are not of high quality, then we must endeavour to fix it. The 
traditional reviews are also incorporating new technology. The Cochrane 
Collaboration’s recent advance in the area of living systematic reviews that are 
“continually updated, incorporating relevant new evidence as it becomes available”, 
offers significant opportunity to reduce the amount of time and effort it takes to 
update high level evidence [65, 66]. This will be invaluable in digital health research 
and evidence base building. As the supporting technologies of automation and 
machine learning continue to improve and become widespread, more time and 
human effort will be saved, and the easier it will be to update the evidence [67].  
Conclusion  
Smartphone popularity and mHealth apps provide a huge potential to improve 
health outcomes for millions of patients. However, we found only a small fraction of 
the available mHealth apps is tested and the body of evidence is low quality. Our 
recommendations for improving the quality of evidence, and reducing research 
waste and potential harm in this nascent field include encouraging app effectiveness 
testing prior to release, designing better trials, and conducting better reviews with 
robust risk of bias assessments. Without adequate evidence to back it up, digital 
medicine and app “prescribability” might stall in its infancy for some time to come.     
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Supplementary material 4. Complete search strategy 
Medline Ovid 
exp Cell phones/ OR exp Computers, Handheld/ 
AND 
exp Mobile Applications/ OR (Application OR Applications OR App OR Apps OR Intervention OR 
Interventions).tw. 
AND 
exp Self care/ OR exp Life style/ OR exp Patient compliance/ OR exp Patient Care/ 
OR 
(Smartphone OR Smart-phone OR Smart phone OR Smartphones OR Smart-phones OR Smart phones 
OR Mobile OR Tablet OR Tablets OR iPhone OR Android).tw. 
ADJ2 
(Application OR Applications OR App OR Apps OR Intervention OR Interventions).tw. 
AND 
(Utilize OR Utilizing OR Administer OR Administering OR Assist OR Manage OR Management OR Role 
OR Roles OR Tested OR Increase OR Increased OR Increasing).tw.  
AND 
exp Patients/ OR (Patient OR Patients OR Population OR Populations OR Public OR Group OR Groups 
OR Chronic OR Acute OR Behavior OR Behaviors OR Behavioral OR Behaviour OR Behaviours OR 
Behavioural).tw. 
AND 
exp "Outcome Assessment (Health Care)"/ OR (Outcome OR Outcomes OR Efficacy OR Effectiveness 
OR Improve OR Improved OR Improvement OR Improvements OR Reduce OR Reduced OR Reduction 
OR Reductions).tw. 
AND 
meta analysis.mp,pt.OR review.pt.OR search.tw. OR searched.tw. OR searches.tw. 
 
 
Cochrane Database of Systematic Reviews 
 
([mh "Cell phones"] OR [mh "Computers, Handheld"]) 
AND 
([mh "Mobile Applications"] OR (Application OR Applications OR App OR Apps OR Intervention OR 
Interventions).tw.) 
AND 
([mh "Self care"] OR [mh "Life style"] OR [mh "Patient compliance"] OR [mh "Patient Care"]) 
OR 
(Smartphone OR Smart-phone OR Smart phone OR Smartphones OR Smart-phones OR Smart phones 
OR Mobile OR Tablet OR Tablets OR iPhone OR Android):ti,ab 
NEAR2 
(Application OR Applications OR App OR Apps OR Intervention OR Interventions):ti,ab 
AND 
(Utilize OR Utilizing OR Administer OR Administering OR Assist OR Manage OR Management OR Role 
OR Roles OR Tested OR Increase OR Increased OR Increasing):ti,ab 
AND 
[mh Patients] OR (Patient OR Patients OR Population OR Populations OR Public OR Group OR Groups 
OR Chronic OR Acute OR Behavior OR Behaviors OR Behavioral OR Behaviour OR Behaviours OR 
Behavioural):ti,ab 
AND 
[mh "Outcome Assessment (Health Care)"] OR (Outcome OR Outcomes OR Efficacy OR Effectiveness  
OR Improve OR Improved OR Improvement OR Improvements OR Reduce OR Reduced OR Reduction 
OR Reductions):ti,ab 
Embase  
('mobile phone'/exp OR ‘microcomputer'/exp) 
AND 





('Self care'/exp OR 'Lifestyle'/exp OR ‘Patient compliance'/exp OR 'Patient Care'/exp) 
OR 
((smartphone OR 'smart phone' OR smartphones OR 'smart phones' OR mobile OR tablet OR tablets 
OR iphone) 
NEAR/2  
(application OR applications OR app OR apps OR intervention OR interventions)):ab,ti 
 
AND 
(Utilize OR Utilizing OR Administer OR Administering OR Assist OR Manage OR Management OR Role 
OR Roles OR Tested OR Increase OR Increased OR Increasing):ti,ab 
AND 
'Patient'/exp OR (Patient OR Patients OR Population OR Populations OR Public OR Group OR Groups 
OR Chronic OR Acute OR Behavior OR Behaviors OR Behavioral OR Behaviour OR Behaviours OR 
Behavioural):ti,ab 
AND 
'Outcome Assessment’/exp OR (Outcome OR Outcomes OR Efficacy OR Effectiveness OR Improve OR 




meta-analys* OR search:ti,ab OR review:it 
 
Web of Science 
Refined by: DOCUMENT TYPES: ( REVIEW ) 
 
Smartphone OR Smart-phone OR “Smart phone” OR Smartphones OR Smart-phones OR “Smart 
phones” OR Mobile OR Tablet OR Tablets OR iPhone OR Android 
AND 
Application OR Applications OR App OR Apps OR Intervention OR Interventions 
AND 
Utilize OR Utilizing OR Administer OR Administering OR Assist OR Manage OR Management OR Role 
OR Roles OR Tested OR Increase OR Increased OR Increasing 
AND 
Patient OR Patients OR Population OR Populations OR Public OR Group OR Groups OR Chronic OR 
Acute OR Behavior OR Behaviors OR Behavioral OR Behaviour OR Behaviours OR Behavioural 
AND 
Outcome OR Outcomes OR Efficacy OR Effectiveness OR Improve OR Improved OR Improvement OR 
Improvements OR Reduce OR Reduced OR Reduction OR Reductions 
AND 
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The previous chapter found that a very small percentage of all available apps has 
been rigorously tested. We also identified multiple research gaps in testing and 
reporting of mHealth trials. Despite the thin evidence base, mHealth apps still hold 
potential as a non-drug intervention. 
This chapter will start to explore the perceptions of general practice patients and 
GPs around mHealth apps and the possibility of app prescription. Barriers and 
facilitators identified in this study will help inform subsequent studies, especially 
the development of an intervention to overcome some of the barriers.  
Manuscript of this chapter is published in the Journal of Medical Internet Research 
mHealth and uHealth. Work arising from this chapter has been presented at the 







Background: The ubiquity of smartphones and health apps make them a potential 
self-management tool for patients that could be prescribed by medical professionals. 
However, little is known about how Australian general practitioners (GPs) and their 
patients view the possibility of health app prescription.  
Objective: To determine barriers and facilitators to prescribing mHealth apps in 
Australian general practice from the perspectives of GPs and patients.  
Methods: Semi-structured interviews were conducted in Australian general 
practice settings. GPs and patients were purposively sampled. Interviews were 
audio-recorded and transcribed. Transcripts were coded and analysed thematically 
by two researchers.  
Results: Twenty GPs and 15 adult patients were interviewed. From the GPs’ 
perspectives barriers to prescribing apps were: a generational difference in the 
digital propensity for GPs and patients; lack of knowledge of prescribable apps and 
trustworthy sources to access them; the time commitment required of GPs and 
patients to learn and use the apps; and concerns about privacy, safety, and 
trustworthiness of health apps. Facilitators from GPs’ perspectives were 
trustworthy sources to access prescribable apps and information, and younger 
generation and widespread smartphone ownership. From patients’ perspectives, 
the main barriers for older patients and the usability of the apps.  Patients were not 
concerned about privacy and data safety issues regarding health app use. The 
facilitators for patients were the ubiquity of smartphones and apps especially for 
the younger generation, and recommendation of apps by doctors. Evidence of 
effectiveness was identified as an independent theme from both GPs’ and patients’ 
perspectives.   
Conclusion: mHealth app prescription appears to be feasible in general practice. 
The barriers and facilitators identified from the GPs and patients’ perspectives 
overlapped, though privacy was of less concern to patients. Involvement of HCPs 
and patients is vital for successful integration of effective, evidence-based mHealth 






The number of smartphones and mobile heath (mHealth) apps has risen globally, 
with Australians at the forefront of smartphone ownership near 90% of the 
population [1]. In addition to fitness and wellness, mHealth apps are primarily 
created for and can benefit patients in managing chronic diseases [2]. More than half 
of US consumers have downloaded at least one mHealth app [3]. Despite the high 
initial uptake of apps, user retention rates can be low and the duration of app usage 
can be short[4, 5]. However, according to the AppScript app prescription platform 
user data, prescribed mHealth apps have a higher retention rate than the non-
prescribed apps [2].  
Healthcare professionals prescribe mHealth apps in their practice in varying 
degrees [6-9]. Although relevant professional organizations provide some guidance 
on how to prescribe mHealth technology in clinical practice, HCPs are often left to 
navigate this new area on their own [10-12]. A systematic review by Gagnon et al 
identified about 180 individual barriers and facilitators to adoption of mHealth by 
HCPs, about third of which reflects factors directly relevant to their knowledge, 
attitude and acceptance of mHealth [13]. However, these findings were not specific 
to general practice. 
In Australia, the Royal Australian College of General Practitioners (RACGP) offers 
limited guidance on mHealth apps. The college also has been collecting basic data on 
providers’ app usage as part of their Annual Technology survey [14]. However, the 
survey has not explored the barriers to mHealth app adoption in-depth. It is 
essential to explore the issues around app prescription in general practice in order 
to devise effective interventions to overcome the barriers perceived by the 
practitioners. Therefore, the objectives of this study were to determine the barriers 
to and facilitators of the prescription of mHealth apps in Australian general practice 
from the perspectives of general practitioners and their patients.  
4.3 METHODS 
PARTICIPANTS 
We conducted one-to-one semistructured interviews with 20 Australian general 




face) in South East Queensland (Australia) general practices between July and 
December 2017. We recruited the participants using purposive sampling to ensure 
a diverse range of years of experience and age. Recruitment was done mainly 
through snowballing via colleagues, organizational contacts, and via initial 
participants. Participation in the interviews was voluntary and written informed 
consent was obtained from each participant before the interview. GPs were 
interviewed in their consultation rooms or over the phone. Patients were 
interviewed in the waiting area of the clinic if privacy was ensured.  
PROCEDURE 
We chose semistructured interviews as they allow for flexibility to explore a new 
subject yet are structured enough to achieve the study aim. The interview questions 
were developed by the authors, piloted with three academic GPs, and revised before 
the study. The questions were designed to explore participants’ attitudes toward 
smartphone health apps, their thoughts on the possibility of prescribing health apps, 
and perceived potential barriers and facilitators to prescribing apps in general 
practice consultations (Figure 8). Toward the end of the interview, participants 
were shown (or in the case of phone interviews, apps were named) 9 examples of 
popular Health & Fitness and Medical apps from the major app stores and 9 
examples of tested and effected apps identified through our earlier study on the 
evidence supporting health and medical apps in order to gauge their general 
familiarity with mHealth apps [15] (Figure 9). No financial or other incentives were 










Figure 9. Example apps shown to interviewees to identify their familiarity with evidence-
based vs. popular mHealth apps 
DATA ANALYSIS 
We planned to interview 15-20 GPs and a similar number of patients. Data 
saturation was fully achieved, ie, no new content emerged after 3 consecutive 
interviews in both cohorts by the time we interviewed 20 GPs and 15 patients, 
therefore validating that our sample size was sufficient. All interviews were 
conducted, audio-recorded, and transcribed verbatim by the first author (OB). 
We employed a thematic analysis methodology described by Braun and Clarke [16]. 
The six phases of analysis were familiarization with the data, coding, generating 
initial themes, reviewing themes, defining and naming themes, and report writing. 
Two researchers (OB, RS) familiarized themselves with the interview transcripts 
and independently coded them. Partially inductive thematic analysis was carried 
out, and generated themes were reviewed in consultation with the third author (TH). 
The results are written up by the first author (OB). 
We used the Consolidated Criteria for Reporting Qualitative Research checklist to 
report the details of our study [17], which is provided as Multimedia Appendix 1. 








About half of the participants were unfamiliar with the Handbook of Non-Drug 
Interventions (HANDI) web resource from the RACGP [18], but upon being 
introduced to it, they all agreed that HANDI would be a trustworthy resource for 
evidence-based apps, consistent with those GPs who were already familiar with 
HANDI. 
BARRIERS 
We identified four themes around barriers to app prescription in general practice. 
The most prominent barrier cited was a generational difference in the overall 
digital propensity for both doctors and their patients. 
Most patients who would benefit from them are elderly and they don’t do 
apps. They don’t do smartphones. That’s the number one barrier. And most of 
our patients who are over 70 will be in that category. Most I would say. [GP7] 
Well, it’s probably my age group more than anything. it’s just I’m not as 
familiar with and as happy around technology as the newer doctors… I do feel 
it’s important to try to learn it because it’s part of the future… so it’s that 
technology I think is the main barrier as far as being used to it. I think we 
need to but it’s just hard to do. Can we get away with it? I guess that’s what’s 
happening to a lot of older doctors is seeing if we really need to do it or not. 
[GP5] 
GPs with more than 20 years of experience appeared more likely to find mHealth 
apps a “gimmick” and less likely to consider using them in their practice. 
I think it would be [possible to prescribe apps]. The trouble is I think they’re a 
bit of a gimmick. I mean we’ve always had accessories to health. When I was a 
young doctor people would bring in their calendars which showed when their 
next periods are. Now they pull out their phones… you find the phone is slower 
than the calendar because the calendar… is there and you’d be able to see it 
visually, whereas a phone, they’re pulling it out… trying to find it miss it… then 
the reception is not good and it takes ages for it to download. So, I don’t really 
find them a step forward. They probably are for the person using them at 
home. But in the consultation, they’re often not a step forward I find. [GP9] 
GPs who primarily work with elderly patients would not consider using apps as 
potential interventions. The “cut-off age” for recommending apps to patients was 
around 40-60 years. 
For somebody like me, there will be obstacles because I don’t really use apps. 
So, if you’re not comfortable with that sort of things yourself, you have to 
overcome that to recommend it... Even when I’ve learned about them in an 




fact, the only times I ever recommend apps at all are for young people… they 
don’t have to be young-young, even in their 30s, a young professional… But I 
never recommend to people older than that. So, there is obviously a 
generational issue. [GP3] 
However, exceptions to the age-based generalization were commonly mentioned, 
making individual digital propensity a more influential factor than age in deciding 
to prescribe apps. 
I got some elderly patients that don’t use an iPhone too often or an app. But 
there’s a lot of savvy oldies there too. It probably depends on the patient, their 
interests. [GP11] 
GPs also recognize that age is a transient barrier as the younger cohort of patients 
will age and become patients with chronic diseases. 
It is a very good idea and something that can be very useful. But I never know 
which ones are good to use and which population would be good to use them. 
I’m sure it will come especially as right now the younger population are the 
ones who are really into the smartphones and they’ll get older and have 
chronic medical conditions in the next 20 years I’m sure it will there’s going to 
be a big space for these apps. [GP16] 
Another barrier was a lack of knowledge of prescribable apps and a lack of 
trustworthy sources to access them. 
Probably the only other barrier is knowing which apps. And keeping on top of 
all the apps they become available, how much they cost and all those kinds of 
things. [GP20] 
I do. I think it’s something I’m cautious of simply because if it’s not something 
that I know a lot about then I’m a bit more concerned, you know, I don’t really 
wanna recommend something I don’t know the full workings of, especially if 
I’m gonna ask them to buy. There’s so much of me asking them to go on 
medication until I’m confident that money is money worth spent and the 
benefit outweighs the cost, then I’m not really willing to do that. [GP2] 
I think for education it’s really valuable. Ones that I don’t use enough of and 
they all want more information. Otherwise, they’ll just Google some unreliable 
search, and so if I’ve got a good place to go to that’s evidence-based, that’s 
good. [GP18] 
Another barrier was the time commitment required to learn about apps and 
integrating them into consultations as well as the time commitment required of the 




adopt apps into their clinical practice, GPs described needing to be convinced of 
the benefits of using apps. 
And it’s time-consuming to learn about these things. It’s hard enough just 
keeping up with what medicine is doing without this app and that app etc. 
[GP1] 
You’re so busy doing in medicine there’s not a lot of time to go out there and 
research what might need to be done to create an app or even the ones that 
are out there. We’re so rushed for time. You’re competing with lots of other 
demands for your time and energy as well. So that’s a big limiting factor. 
[GP8] 
The patients’ motivation would be a big thing. And the time involved in using 
it would be another big thing for someone who might be busy, for example. I 
don’t think a lot of people have a lot of time to invest in this type of thing. So, I 
think your time, availability, and the motivation behind a patient. [GP15] 
I think for me, it’s just when you are consulting, and you’re busy. To modify the 
practice of what I’m doing, I have to have a pretty good reason for doing it. 
[GP6] 
Another barrier identified was the privacy, safety, and trustworthiness of health 
apps. The GPs perceived issues around privacy and data safety of health apps as 
the ultimate responsibility of the patients, since their complete and ongoing safety 
cannot be guaranteed. Some GPs were aware of how the industry attempts to 
influence health care. 
I personally manage my privacy very, very, very carefully. But I think I leave 
that to the individual patient... and I think that if they’re going to be using 
apps, my perception is that they already have made their own personal 
decisions upon privacy. [GP4] 
I think that’s every day now. I mean the number of times you get on Google 
and then they already go okay well you’ve got this many children, and I know 
that already… that’s the world we live in. I don’t think we’re going to stop that 
by not using an app when we’re on the internet all the time. So, if it’s 
demographic information and I think that’s being collected by a lot of people, 
not just an app, I suppose. [GP20] 
Also, I guess I’m also very wary of who’s paying for it. So, I guess my general 
approach to most things is to think if you’re going to pay for it, then hopefully 
you are bearing the load of what if it’s worth it. If someone else is paying then 
there’s some hidden agenda there, whether it’s a drug company or someone 
else who’s gonna benefit of you having their app on your phone and again 




who’s designed it and what’s the purpose of it and who’s benefiting the most. 
[GP2] 
FACILITATORS 
We identified two main themes around facilitators of mHealth app prescription in 
general practice. One was a trustworthy source for prescribable apps and 
information for GPs. The RACGP was their most preferred trustworthy source to 
vet, endorse and provide prescribable apps as the majority of the GPs were RACGP 
members.  
“Maybe some sort of database of trusted apps that would be recommended for 
certain conditions or treatment strategies. Having a nice little summary of 
things that could be used, because of the sheer number of what's on the market, 
it's hard to really make it part of my regular day-to-day routine... Whereas if 
some organization was to put together a list of you know tried and tested and 
reliable apps then it would be much easier to say “look, you're young you'll 
you've got the time and the patience for it, let's try an app for this problem, and 
this is the one we trust.” (GP15) 
“I think we probably need to have them reliably approved and researched by 
our college. I probably wouldn’t be happy to recommend any without the 
endorsement of the college.” (GP11) 
“… we need more education on which ones to prescribe and which ones not. We 
have the NPS which helps us with prescribing medications. So, if there were an 
organization/body involved with educating GPs on which apps are good and 
useful and provide the right information and are easy to use, that would be 
really helpful.” (GP16) 
GPs recognized that near-universal ownership of smartphones, the ubiquity of 
apps, and younger tech-savvy patients are enablers of app prescription, as this 
facilitates information accessibility and can sometimes provide alternatives that are 
more convenient and lower in cost.  
“I work in an area where there's a lot of young people and most of these people 




not being able to recommend an app so somebody. This hasn't happened yet.” 
(GP12) 
“Apps are quite a neat way of showing somebody all that information without 
having a book to give them. It's often a very low-cost solution if your 
alternatives are costly. And it's very accessible... you don't need to wait for in-
hours care, you can be 10 p.m. at night and do some of the work whether it's 
treatment or information and knowledge that you're sharing that can all be 
done at a time that suits a patient. so that's the kind of value of apps I suppose 
over other resources.” (GP20)  
PATIENTS’ PERSPECTIVES 
Two-thirds of the patients have used or use mHealth apps personally. Most 
commonly used app types were fitness, wellness, and women’s health related apps 
(period, ovulation and pregnancy tracking). Those who did not use any apps said the 
reason was they do not have any need or significant reason to. People often chose 
apps through recommendations by friends or family, directly from app stores or 
through the services they subscribed to such as the local gym. From the list of 
popular and evidence-based apps, they recognized some of the most popular apps 
such as MyFitnessPal and 5K runner, but none of the evidence-based apps.  
BARRIERS 
From the patients’ perspectives, a perceived barrier to using mHealth apps in GP 
consultations was older patients.  
“I don’t think there’d be any problem. But if we’re talking about the elderly, 
they’re not really very computer-savvy. So, they might find it difficult. I have a 
number of friends, even older than me, they don’t wanna use smartphones. It’s 
too much trouble. They just wanna make a phone call and get a text. That’s it.” 
(Pt8) 
“I guess only with the older generation not having smartphones. They would 
not use apps. So that would really be the only problem. Yeah, I wouldn’t see any 
other [issue].” (P2) 




“I think the ease-of-use has to be paramount. Ease of use is gotta be the big issue. 
For me, that was the problem. I can’t speak for other people. I mean I’m pretty 
good with technology, but I just found it very tedious… And I just found it was 
annoying to put data in. That was the issue with it. So, when it becomes difficult, 
I didn’t do it.” (Pt12) 
Data safety and privacy issues related to health app use were not a barrier described 
by the patients interviewed. Patients were more concerned about financial 
information loss than their health-related information. 
“I don’t worry about it too much, privacy stuff, cause I don’t have much to hide. 
Maybe if someone got on to your phone, they could see your personal 
information, they usually have like a passcode for private apps anyway.” (P13) 
“Me personally, no. data safety… it is what it is. I think there are measures in 
place to keep it safe. Other people probably don’t have that opinion. I think 
honestly it is safe enough.” (P15) 
 “I’m more worried about financial stuff than health that would create a 
financial loss. if somebody finds out what my blood pressure is, what’s the big 
deal, right?” (Pt8) 
“I don’t worry about it. well, I’m not really putting anything into an app that is 
that [important]… I mean I don’t know who else in the world cares the day my 
period came or how big the baby is, I haven’t really put in banking details or 
anything. I haven’t used any paid apps.” (Pt6) 
FACILITATORS 
From the patients’ perspectives, the ubiquity of smartphones and apps and young 
patients were perceived facilitators of app prescription.  
“I imagine younger people wouldn’t have any problems” (Pt11) 
“I think it’s quite a common thing now. Everyone has smartphones nowadays. 




Most patients expressed that they think mHealth apps can be beneficial, especially 
when recommended by their doctor and that app prescription by GPs is possible, 
helpful and welcome because it would eliminate the challenge of finding health apps 
for themselves.  
“Great idea if they’re prescribed from a doctor. I don’t think getting them off 
the net without advice would be a good thing. I think it needs to be advised or 
prescribed by someone who knows, and then from there, it can only be a good 
thing, yeah.” (Pt15)  
“Yeah. If my doctor recommended one, I’d probably go with that rather than 
trying to go from the recommendations on iPhone, you know, the stars, from 
the app stores. I mean they are helpful too what other users have found, cause 
a lot of apps crash and have problems if they’re not maintained and upgraded, 
but yeah if a doctor was recommending one, I’d probably use it.” (Pt9) 
“if there are multiple people being like “this is really good. This has helped me 
with this…” then I’ll actually go have a look. If I like it for more than a week, 
then I’ll just continue using it. I went through a lot [of apps] before finding the 
one that wasn’t an effort to use, one that was just easy. I went through probably 
ten to find one I actually liked, which is a bit annoying. It kind of turns you off 
that. So, if there was one or two that all doctors recommended then people 
would probably more likely to use them” (Pt1) 
A theme identified from both the GPs and patients’ perspectives that could not be 
clearly categorized as a barrier or facilitator was evidence of the effectiveness of 
the apps. GPs expressed they would not want to prescribe apps without evidence 
behind it, yet they also feel that simple apps do not need high levels of evidence.  
“…as it applies to anything in medicine, I think it would need a reasonable 
degree of efficacy to run with it. You know, you can’t just have an app for the 
sake of having an app.” (GP1) 
“… [evidence is] pretty important to officially recommend. Some of it is common 
sense. Like something to log your blood pressure and mood diary is self-




of wanna know if there’s good evidence so that it’s reasonably well made. 
Especially if you’re going to spend money on it.” (GP14) 
Most patients viewed the evidence of effectiveness of apps to be important in the 
same way as the standards required of pharmaceutical interventions. Some were 
not concerned about the effectiveness and preferred their own evaluations and 
freedom to make the ultimate decision. 
“Very important. It’s like anything in health, it’s like medication, if a doctor is 
gonna recommend something, they have to know it works. Cause it might not 
be suitable for somebody, and if that person is to use something that’s not 
suitable then that could have a bad effect instead of a good one.” (Pt13) 
“Definitely, yea. I would want one that has references, the app that I use have 
medical references they’ve sourced the information. Otherwise, anyone could 
be sitting home and writing an app.” (Pt6) 
“I’m not too worried about that. I just get on and try it, if it works for me then 
that’s great. It if doesn’t then I’ll just delete it if it’s not gonna do what I needed 
it to do for me… I mean as long as it’s our choice to use them or not. I mean up 
to us, they can make a recommendation, but if we find it’s not suitable or it 
doesn’t work. and If it does then great if it makes our life easier, it’s a fast and 






In this study of the barriers to and facilitators of mHealth app prescription in 
Australian general practice, all patients and GPs recognized that mHealth apps could 
be beneficial, and app prescription is achievable. From the GPs’ perspective, uptake 
is hindered by barriers around a generational difference in the digital propensity for 
both GPs and patients, lack of knowledge of prescribable apps and lack of 
trustworthy source to access them, time commitments required of the GPs and 
patients, and privacy, safety, and trustworthiness of health apps. 
Both patients and GPs cited the old age of patients as a barrier to app prescription, 
although also offered examples of exceptions to this age-related division of digital 
propensity. Annual mobile consumer surveys showing that older age groups have 
seen the highest increase in smartphone ownership in Australia [19]. Doctors and 
patients also believed that the ubiquity of smartphones and apps, and young 
patients are facilitating factors as Australians approach “peak smartphone”—the 
peak level of usage before the vast majority of consumers to begin actively limiting 
their phone use [20]. Almost all the interviewed GPs reported using apps personally 
and professionally; however, they do not recommend specific apps to patients. 
Instead, they remind patients of the availability of mHealth apps in the general area 
of focus (eg, mindfulness) should they wish to use them. 
The evidence base (weak or strong) for mHealth apps emerged as an important 
theme as a barrier or facilitator. Patients viewed doctors as a trustworthy source of 
health apps, and the GPs acknowledged that they needed a trustworthy source for 
prescribable apps as they have neither the knowledge nor time to find such apps 
themselves. A national-level professional organization such as the RACGP is well-
placed to address this barrier. One of the many resources they provide for GPs is 
HANDI—a database of effective nondrug interventions, which includes several 
mHealth apps [18]. However, half of the GPs interviewed in this study were not 
familiar with or commonly used HANDI, but all agreed that RACGP is the most 
trusted source for them to access professional and practice-related information and 
guidance. The majority of participants recognized a few of the most popular apps 
from app stores and fewer apps from the evidence-based apps list, emphasizing the 




Several comparable studies have explored barriers and facilitators to novel 
technology adoption in medical practice. Many studies report a lack of education 
and training as one of the most common barriers that face health care providers in 
adopting new technology in health care [13,21,22], and our study echoes this. 
Furthermore, the potential to increase doctors’ time strain and workload are 
universally common factors of poor uptake of new health technologies [23-25]. 
Brandt et al found that the experiences of GPs with eHealth support for lifestyle 
changes were an essential factor in recommending it for their patients [26]. Our 
findings also emphasize the digital propensity of the health care providers and 
patients would make a big difference in uptake of mHealth apps. Building on this 
finding and educating and supporting GPs so they understand the value of new 
technology such as the potential to save consultation time and keep patients 
connected and motivated between consultations can help mitigate against these 
barriers and help them recommend apps to their patients with confidence. 
Recent research suggests that individuals with poor self-reported health and low 
rates of physical activity were the least likely to report downloading and using these 
health tools [27]; however, patients adhere better to prescribed apps [2] beyond the 
typical one week of usage [4,5]. Thus, the official prescription of apps by trusted 
medical practitioners might help increase the uptake of effective health apps among 
such patients who would benefit the most. Future studies should measure the real-
world adherence of the patients following app prescription by health professionals. 
The present qualitative study appears to be the first of its kind to explore the 
perspectives of GPs and patients regarding mHealth app prescription in Australian 
general practice. The barriers identified in this study were added to the mHealth 
section of the RACGP Annual Technology survey in 2017 to explore further how they 
would rank among a national sample of GPs [28]. The question about barriers to app 
prescription gathered over six hundred responses and the top barriers reflected the 
central theme identified in this study, which was lack of knowledge of effective apps 





Limitations of this study include a small sample size that skewed towards relatively 
healthy patients from high socioeconomic areas and GPs from the metropolitan area. 
Although we attempted to mitigate this limitation by purposively sampling 
participants from a variety of age and work experience, future studies should target 
patients with long-term medical conditions, those from rural and remote areas, and 
low socioeconomic areas. Other limitations include lack of triangulation of the 
results, member checking, a reflection of possible interviewer bias about the 
potential of apps, and not piloting the interview questions with patients. 
Conclusions 
mHealth app prescription appears to be feasible in general practice. The barriers 
and facilitators we identified from both GPs and patients widely overlapped. The 
involvement of all stakeholders of consumer mobile technology, medical 
professionals, and patients is vital in the successful integration of mHealth apps with 
clinical practice. The findings of this study will inform the development of effective 
interventions to overcome the identified barriers and help the adoption of health 
apps to general practice to patients’ benefit. 
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The previous study identified several barriers and facilitators to app prescription 
from the perspectives of both patients and GPs. Main barriers from the GPs’ 
perspectives were a (1) generational difference in the digital propensity for both the 
GPs and patients; (2) lack of knowledge of prescribable apps and lack of reliable 
source to access apps; (3) the time commitment required of GPs and patients; and 
(4) issues around privacy, safety and trustworthiness of health apps. 
This chapter reports on the findings of the mHealth section of the 2017 annual 
technology survey conducted by the Royal Australian College of GPs in 2017 we 
helped to develop. Questions about GPs’ current use of mHealth apps, barriers they 
perceive, and potential solutions were asked based on the findings of the previous 
study.   
This chapter is published under the title “Current Knowledge and Adoption of 
Mobile Health Apps Among Australian General Practitioners: Survey Study” in the 
Journal of Medical Internet Research mHealth uHealth in Jun 2019. Work arising 







Background: Mobile health (mHealth) apps can be prescribed as an effective self-
management tool for patients. However, it is challenging for doctors to navigate 350 
000 mHealth apps to find the right ones to recommend. Although, medical 
professionals from many countries are using mHealth apps to varying degrees, 
current mHealth app use by Australian general practitioners (GPs) and the barriers 
and facilitators they encounter when integrating mHealth apps in their clinical 
practice have not been reported comprehensively.  
Objectives: The objectives of this study were to (1) evaluate current knowledge and 
use of mHealth apps of GPs in Australia; (2) determine the barriers and facilitators 
to their use of mHealth apps in consultations; and (3) explore potential solutions to 
the barriers.  
Methods: We helped the Royal Australian College of General Practitioners (RACGP) 
to expand the mHealth section of their annual technology survey for 2017 based on 
the findings of our semi-structured interviews with GPS to further explore barriers 
to using mHealth apps in clinical practice. The survey was distributed to the RACGP 
members nationwide between 26 October - 3 December 2017 using Qualtrics online 
survey tool.  
Results: A total of 1014 RACGP members responded (response rate 4.6% 
[1014/21,884], completion rate 61.2% [621/1014]).  The median years practiced 
was 20.7 years. Two thirds of the GPs used apps professionally in forms of medical 
calculators and point-of-care references. A little over half of the GPs recommended 
apps for patients daily (12.9%, n=80/621), weekly (25.6%, n=161/621), or monthly 
(13.4%, n=83/621). Mindfulness and mental health apps were recommended most 
often (32.5%, n=337/1036), followed by diet and nutrition (13.9%, n=144/1036), 
exercise and fitness (12.7%, n=132/1036), and women’s health (10%, n=104/1036) 
related apps. Knowledge and usage of evidence-based apps from the Handbook of 
Non-Drug Interventions (HANDI) were low. The prevailing barriers to app 
prescription were lack of knowledge of effective apps (59.9%, n=372/621) and lack 
of trustworthy source to access them (15.5%, n=96/621). GPs expressed their need 




overcome these barriers. They reported a preference for online video training 
material or webinar to learn more about mHealth apps.  
Conclusion: Most GPs are using apps professionally but recommending apps to 
patients sparingly. The main barriers to app prescription were lack of knowledge of 
effective apps and lack of trustworthy source to access them. A curated compilation 
of effective mHealth apps or an App library specifically aimed at GPs and HCPs 






Over the past decade, smartphones have become an inseparable part of modern 
living, and mHealth apps have started to establish their place in healthcare [1]. If 
proven to help achieve measurable clinical improvements in patients’ conditions, 
mHealth apps can be officially prescribed or recommended by general practitioners 
(GPs) [2]. However, with 350 000 apps available in the medical, and health and 
fitness categories in the major app stores, it is challenging for GPs to find 
prescription quality mHealth apps from the app stores themselves to use in their 
clinical practice [3]. To overcome this issue, a number of initiatives like the NHS App 
library in the UK [4] and Health Navigator App library in New Zealand [5] have been 
set up to help doctors. In Australia, official effort to support app prescription does 
not exist yet, but there are small initiatives such as the Victorian Health Promotion 
Foundation Healthy living apps guide aimed at the general public [6], and the 
Handbook of Non-Drug Interventions (HANDI) project by the Royal Australian 
College of General Practitioners (RACGP) [7], which is a repository of evidence-
based non-pharmaceutical interventions for general practitioners (GPs).  
Health care professionals’ use of mHealth apps and mobile technologies have been 
explored in several recent reports from the USA [8], UK [9], France [10] and Turkey 
[11]. At least half of the surveyed GPs, specialists, dieticians and pharmacists 
reported to recommend mHealth apps to patients, except for the French study of 
GPs, which reported half that rate. Barriers perceived by the HCPs regarding 
mHealth integration to their clinical practice include a variety of issues from 
infrastructure related problems such as Wi-Fi coverage and interoperability with 
the existing medical software, to more specific data security, content reliability, and 
a universal lack of awareness of the effective apps to use. These all echo the findings 
of an earlier systematic review by Gagnon et al [12], which summarized the barriers 
and facilitators to mHealth adoption by HCPs from around the globe. 
Australian GPs’ mHealth adoption has been explored only briefly as part of the 
annual technology survey by the RACGP since 2015. The purpose of this survey is to 
explore technological innovation and adoption in general practice including mobile 
technology [13]. Following our qualitative study with GPs on the barriers and 




to expand the mHealth section for 2017 to better understand the specific barriers to 
health app use in the wider Australian context. Thus, our objectives for the current 
study were to: (1) explore knowledge and use of health apps of practicing GPs in 
Australia in more detail; (2) determine the barriers and facilitators to prescribing 
health apps in GP consultations in a wider cohort of GPs; and (3) explore potential 
solutions to some of the barriers.  
5.3 METHODS 
We used the Checklist for Reporting Results of Internet E-Surveys (CHERRIES) as 
recommended by Journal of Medical Internet Research (JMIR) as a reporting guide 
for this study [14]. The data for this study collected as part of the 2017 RACGP 
Technology survey, which was conducted using an online survey tool (Qualtrics, 
Provo, Utah, USA) between 26 October - 3 December 2017 in Australia [15]. We used 
convenience sampling and the survey link was emailed to all RACGP members, 
which include GP trainees, fellows, and vocationally registered GPs, as well as 
practice managers and clinic owners. Only the GPs currently practicing in Australia 
were able to advance and answer all questions. For GP registrars and GPs who were 
not practicing currently or not practicing in Australia, the survey ended after the 
relevant questions. Ethics approval was obtained from the RACGP National 
Research and Evaluation Ethics Committee (NREEC). 
The previous year’s survey contained six questions regarding GPs’ use of mobile 
devices and mHealth apps out of 46 questions [13]. Based on the findings of our 
semi-structured interview study with 20 GPs that explored the barriers and 
facilitators to using mHealth apps in practice, we collaborated with the RACGP to 
expand the mHealth section questions for the 2017 survey making them more 
specific and informative. The questions were pilot-tested with the co-authors and 
academic GP colleagues and refined iteratively. This paper reports the analysis of 16 
questions pertaining to demographic information, mobile device and health apps 
usage out of the total 50 questions (Table 6).  
Data were extracted from Qualtrics and descriptive statistics were conducted using 
Microsoft Excel (2016). Answers to the open-ended questions were coded according 






could benefit their day-to-day practice (n=136; 39%), not being confident on how to 
use mobile technology safely in daily practice (n=68; 20%), and the practice they 
work for did not allow the use of personal mobile devices in practice (n=51; 15%). 
Other reasons (n=91; 26%) included not wanting to use personal mobile devices in 
consultations, their desktop computer being sufficient and more convenient, and not 
needing to use mobile devices altogether. About two thirds of the GPs used health 
apps themselves (n=440; 64%) mostly in the form of point-of-care references like 
UpToDate, eTG, Medscape (n=298; 25%), and medical calculators (n=137; 11%). 
A little over half of the GPs recommended apps for patients daily (n=80; 13%), 
weekly (n=161; 26%), or monthly (n=83; 13%). The other half rarely (n=210; 34%) 
or never (n=87; 14%) recommended apps. Figure 10 shows the app 
recommendation frequency appears to decrease with the number of years practiced 
as a GP. GPs most commonly recommended mindfulness and mental health (n=337; 
33%), diet and nutrition (n=144; 14%), exercise and fitness (n=132; 13%), and 
women’s health (n=104; 10%) related apps to patients. Examples of the specific 
apps they use included Smiling Mind, Headspace, MyFitnessPal, and Easy Diet Diary. 
The question about evidence-based apps from the HANDI project revealed that 
smoking cessation apps were reported as prescribed 119 times, insomnia apps 39 
times, and the ankle exercise app 7 times. However, the majority of the GPs did not 







provides web-based Apps library for doctors, but also introduced an app 
prescription platform for the GPs [17]. Similarly, for Australia, there is an 
opportunity for a professional organization such as the RACGP to lead the way to 
address the major barriers identified in this study. Although the inclusion of 
mHealth apps in the HANDI project is a starting place, more work needs to be done 
to raise awareness and profile of this initiative. Furthermore, integration of 
approved apps into the electronic medical systems to streamline the usability as 
well as providing continuing professional development trainings for up-to-date 
information on mHealth apps would enhance the use of evidence-based apps in 
clinical practice. 
The strengths of this study include expanding on and improving previous year’s 
mHealth questions with more specific questions regarding evidence-based app 
adoption and barriers in general practice based on our qualitative research on GPs 
to get obtain more comprehensive data on a nationally representative sample. Our 
response rate of 4.6% was similar to that of other mHealth app surveys undertaken 
on HCPs [9, 10]. The completion rate of the mHealth section was uniformly high 
although skipping questions was allowed.  
The limitations of our survey study are the selection bias inherent in survey studies, 
and the low response rate. However, the median age, median years practiced, and 
geographical distribution data of the GPs in our study were comparable to those of 
the national GP workforce data [16], thus supporting the demographic 
representativeness of our study population. A reason for the low response rate 
could be survey fatigue due to the fact that the mHealth questions analysed here 
were a part of a larger survey on technological innovation in general practice [18]. 
The challenge for conducting survey studies on medical professionals is a balancing 
act between conducting a dedicated survey only focusing on single topics and the 
burdening of GPs with yet another survey. To increase the response rate of surveys 
that involve medical professionals, certain strategies could be undertaken such as 
offering more attractive incentives to participate and randomly sampling the cohort 




mHealth apps have a unique niche in the future of healthcare. However, the evidence 
of their effectiveness, safety and usability issues are challenged by both the fast-
evolving nature of the software and commercial aspects of the technology that can 
be easily exploited. HCPs need guidance on the quality of mHealth apps to assist in 
their adoption into clinical practice. In the absence of notable initiatives from 
government or private sectors to regulate app quality and safety, professional 
organizations must take the lead to address this challenge.  
Acknowledgements: We wish to thank Gisele Rocha, RACGP Project Manager, for 
leading the development and facilitating modifications to the 2017 RACGP 
technology survey. 
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The previous chapters identified the most important barriers facing GPs in using 
mHealth apps in their practice. The one barrier we were able to address was the lack 
of knowledge of prescribable apps and lack of trustworthy source to access them.  
This chapter reports on the details of our feasibility study to increase the uptake of 
mHealth app prescription by Australian GPs. The timeline of the study is shown in 
Figure 12. 
 
Figure 12. Timeline of App prescription study: four data collection points interjected halfway 
by app video introduction, bookended by enrolment survey and exit interview. 
The manuscript of this study is published in the Journal of Medical Internet Research 
mHealth uHealth. Work arising from this study has been presented by invitation at 
the Northern Territory Primary Health Network’s learning and teaching conference 
COMPASS in Aug 2019 and at the National Health and Medical Research Council’s 







Background: The evidence of effectiveness of mobile health (mHealth) apps and 
their usability as non-drug intervention in primary care are emerging around the 
globe. 
Aim: This study aimed to explore the feasibility of mHealth app prescription by 
general practitioners (GPs) and to evaluate the effectiveness of an implementation 
intervention to increase app prescription. 
Methods: A single-group, before-and-after study was conducted in Australian 
general practice. GPs were given prescription pads for 6 mHealth apps and reported 
the number of prescriptions dispensed for 4 months. After the reporting of month 2, 
a 2-minute video of one of the apps was randomly selected and sent to each GP. Data 
were collected through a prestudy questionnaire, monthly electronic reporting, and 
end-of-study interviews. The primary outcome was the number of app prescriptions 
(total, monthly, per GP, and per GP per fortnight). Secondary outcomes included 
confidence in prescribing apps (0-5 scale), the impact of the intervention video on 
subsequent prescription numbers, and acceptability of the interventions. 
Results: Of 40 GPs recruited, 39 commenced, and 36 completed the study. In total, 
1324 app prescriptions were dispensed over 4 months. The median number of apps 
prescribed per GP was 30 (range 6-111 apps). The median number of apps 
prescribed per GP per fortnight increased from the pre-study level of 1.7 to 4.1. 
Confidence about prescribing apps doubled from a mean of 2 (not so confident) to 4 
(very confident). App videos did not affect subsequent prescription rates 
substantially. Post-study interviews revealed that the intervention was highly 
acceptable. 
Conclusion: mHealth app prescription in general practice is feasible, and our 
implementation intervention was effective in increasing app prescription. GPs need 
more tailored education and training on the value of mHealth apps and knowledge 
of prescribable apps to be able to successfully change their prescribing habits to 
include apps. The future of sustainable and scalable app prescription requires a 





More than 350,000 apps exist in the Medical and Health and Fitness categories in 
major app stores [1], with downloads and revenues in the billions [2]. Their 
popularity and potential to influence health-related behaviors make their 
integration to medical practice imminent [3]. Pragmatic studies of app prescription 
in primary care have been emerging around the world with varied interventions and 
results [4-6]. To assist the integration of apps into clinical practice, mobile health 
(mHealth) app repositories have been created, including the National Health Service 
App library in the United Kingdom [7], Health Navigator in New Zealand [8], and 
other private entities such as AppScript [9] and the Organization for the Review of 
Care and Health Applications [10].  
Given the potential of mHealth apps to help improve the self-management of chronic 
conditions, we explored their value in general practice. Previously, in an overview 
of systematic reviews, we explored the possibility of simple integration of mHealth 
apps into the general practice setting and proposed a concept of “prescribable” 
mHealth apps. These were defined as proven effective (that is, shown to help achieve 
measurable clinical improvements in patients’ conditions), in addition to being 
standalone and currently available in the app stores [11].  
We also explored the potential barriers to app integration in Australian general 
practice [12]. Patients expressed their preference for doctor-recommended apps; 
however, doctors were overwhelmed by the sheer number of available apps and 
faced 2 major barriers: not knowing of many prescribable apps and the lack of 
trustworthy source to access such apps. To address these barriers, we developed a 
brief implementation intervention. Objectives of this study were to explore the 
feasibility of app prescription by general practitioners (GPs) and to evaluate the 
effectiveness of an implementation intervention to increase uptake of app 





STUDY DESIGN AND SETTING 
We employed a single group, before-and-after design. Our study was conducted in 
Australian general practice setting. Ethics approval was obtained from the Bond 
University Human Research Ethics Committee (#OB00017).   
PARTICIPANTS AND RECRUITMENT 
GPs currently working in Australia at least two days a week were eligible to 
participate in our study. Information about the study was distributed at GPDU2018 
and GP18 conferences and posted to a closed Facebook group called GPs 
DownUnder (GPDU). Recruitment occurred from June through to November 2018 
and data collection from September 2018 until May 2019. Upon the completion of 
the study, GPs were thanked with AUD$ 50 gift cards.  
INTERVENTION 
There were two parts to the intervention. Firstly, prescription pads for 6 apps were 
developed (Figure 13). These apps were chosen because they address conditions 
relevant in general practice, have either direct trial evidence (This Way Up: 
Managing Depression (St. Vincent’s Hospital Sydney Ltd) [13], Tät – Pelvic floor 
exercises (Umeå University, Sweden) [14], Lose-It! (FitNow Inc.) [15, 16], CBT-i 
Coach (US Department of Veteran’s affairs) [17]) or indirect evidence from trials of 
similar apps (Smiling Mind (Smiling Mind Pty Ltd) [18-20], and  Quit Now: My 
QuitBuddy (Australian National Preventative Health Agency) [21]). The apps also 
had to have stable content, created or backed by trustworthy not-for-profit 
organizations, and are available for both Apple and Android phones. Five of the apps 
were freely available and one (This Way Up: Managing Depression) had a one-time 
purchase price of AUD $59.99. The cost of apps was not an exclusion criterion as it 
will help assess if the cost is a barrier to app prescription. 
 
The app prescription pads had individually numbered pages with tear-off design. 
Each app prescription page included the app’s full name and logo, download 
instruction, space for the patient’s name, the reason for prescription, and a 




to participating GPs. A letter outlining the study timelines and procedures along 




Figure 13. The six app prescription pads. (A) the front of the prescriptions. Note script 
number in the bottom right corner. (B) the back of the prescriptions with download 
instructions and costs. 
The second part of the intervention was aimed at enhancing uptake. Short videos (2 
min) demonstrating the content, functions, and features of the apps in detail were 
created for each app. A YouTube link to the video randomly selected for each 





Our study aimed to change the prescribing behavior of GPs. Evidence suggests that 
behavioral interventions are more effective and sustainable when guided by 
behavior change techniques. Our prior research helped to identify the target 
behaviors [12]. We based our intervention on the Capability, Opportunity, 
Motivation and Behavior model [22]. Capability to prescribe apps was addressed 
through the list of evidence-based apps and the introductory videos demonstrating 
the content, features, and function of the apps; opportunity was enabled through the 
purposefully designed stand with the prescription pads; and motivation was 
harnessed through the GPs’ expressed interest in the study that demonstrates their 
belief that app prescription would be a good thing to do [23]. 
PROCEDURES 
At the beginning of the study, participants signed consent forms and answered the 
prestudy questionnaire via the web-based SurveyMonkey (SurveyMonkey Inc, San 
Mateo, CA) tool. The survey collected demographic data, contact details, current app 
prescription rate in the preceding 2 weeks (self-reported in ranges: 0, 1-5, 6-10, >10 
times), and level of confidence around app prescription.  
The official commencement dates for the study were recorded as the date that each 
participant reported they started using the pads. Every 4 weeks following 
commencement, participants were asked to send a photo of the prescription pads 
electronically to the research team to provide details of the number of prescriptions 
for each app within that month. If participants took leave from work, the reporting 
dates were adjusted to allow for a full 4-week reporting period. 
Qualitative semistructured interviews (10-15 minutes) were conducted and audio 
recorded at the end of the study, either face-to-face or by telephone, to gather 
feedback on the intervention. GPs were asked about their knowledge of other apps 
and relevant resources outside the study, including the Handbook of Non-Drug 
Interventions (HANDI) project by the Royal Australian College of General 
Practitioners, which includes a number of mHealth apps. Interviews were 
transcribed verbatim, coded by the lead researcher (OB), and thematically analyzed 




scalability of the intervention to Australian GPs. The thematic analysis was done in 
consultation with a second author (TH).   
SAMPLE SIZE 
Prior data [12] indicated that the difference in the response before and after is 
normally distributed with a standard deviation of 10, and a baseline mean of 2 apps 
prescribed per month per GP.  We calculated that we needed 24 participants to have 
80% power (with alpha=0.05) to detect an increase of app prescription by at least 6 
per month. Taking attrition into account, we planned to recruit 30 GPs for the study.  
OUTCOMES 
Data on app usage were collected for the 2-week period prior to study 
commencement and then every month for 4 months. The primary outcome of the 
study was the number of app prescriptions dispensed in total, as an average per 
month, per GP, and per GP per fortnight. We calculated the median number of apps 
recommended by a GP per fortnight using the following formula: 
m=l + (w(n/2-c))/f 
where l is the lower limit of the bin (range) containing the median, w is the width of 
the bin, n is the total population, c is the cumulative count (frequency) up to l, and f 
is the count in the median bin. 
Prestudy raw numbers are provided in Table 1 (m=1.7 [1 + (5(39/2-17))/19]). 
Poststudy numbers are given in the Results section (m=4.1 [1 + (5(39/2-0))/31]). 
 
Secondary outcomes were confidence around prescribing apps (measured on a 5-
point Likert scale; pre-study and poststudy); the number of intervention video 
views and their impact on the subsequent prescription numbers; and attrition rate. 
In addition, the acceptability of the interventions to GPs and their feedback on the 
interventions were explored in semi-structured interviews. Descriptive statistics 
were used to report the frequency of app use at each time point and confidence in 
app prescription. Qualitative data were analyzed thematically. 
 
To conduct an overall analysis of the effect of video exposure on prescription rates 
the 6 separate outcomes (1 for each app) were considered as one overall global 






Figure 15 illustrates the distribution of the total app prescription per GP. According 
to the ITT analysis, a median of 30 apps (range 6-111 apps) was prescribed per GP 
over the 4 months. Every GP prescribed at least one app per fortnight, 31 (31/39, 
80%) GPs prescribed 1-5 apps, 7 (7/39, 18%) prescribed 6-10 apps, and 1 GP 
prescribed more than 11 apps. The GPs’ confidence around prescribing apps 
doubled from a mean of 2 (not so confident) before the study to 4 (very confident) 
at the end of the study: 0/39, not confident at all; 1/39 (3%) not so confident; 12/39 
(31%) somewhat confident; 25/39 (64%) very confident; 1/39 (3%) extremely 
confident. 
 
At the end of the study, the My QuitBuddy app video was viewed 8 times; the Smiling 
mind, Managing Depression, and Lose-It! app introduction videos were viewed 9 
times each; the Tat-Pelvic floor exercise video was viewed 19 times; and the CBT-i 
Coach video was viewed 21 times. We were not able to track whether every GP 
watched the video sent to them. The effects of exposure to app videos are shown in 
Figure 16. Only two of the app videos had a significant effect on the subsequent app 
prescription numbers following the exposure to the video: Smiling Mind app 
prescription increased from 3-4 times per month to 6 times per month, and Lose-it 
app prescription increased by one time. The full analysis is provided in Multimedia 
Appendix 1. A global test for the interaction between exposure and video showed 
strong evidence of heterogeneity (P<.001) indicating the treatment effects were 





Figure 15. Distribution of total app prescription per GP. The red dot indicates the median 
(30). White dots are the participants who dropped out. The dashed circle is the participant 
who never commenced. 
 
Figure 16. Mean number of app prescription per GP before and after the intervention 
video exposure at each month. Only Smiling Mind and Lose-It! videos show a significant 
effect of the subsequent prescription numbers. 
QUALITATIVE INTERVIEWS 
Thirty-nine GPs were interviewed at the conclusion of their participation in the 




prescribing apps as overwhelmingly positive. They liked the size of the prescription 
pad, the information included on it, ease of use and integration into the workflow, 
with the most useful feature identified as the visual cue aspect of the stand. They 
also liked the short length of the videos, yet that they contained sufficient details 
about the apps. Most GPs reported not downloading and interacting with the apps 
themselves. Although most reported having watched the allocated video, many did 
not recall the contents during the post-study interviews.  
 
Two of the 6 study apps were well known to the GPs: 28/39 GPs were already 
familiar with Smiling Mind, and 12/39 GPs with Managing Depression. They had 
been recommending these apps to their patients even before the study and 
appreciated having a formal prescription to give out during the study. Among the 
other apps that GPs recommended, mindfulness and meditation apps (Calm, 
Headspace) were common. Mental health–related apps were the most frequently 
prescribed, and all GPs reported that the overall number of apps they prescribed is 
a reflection of the demographics of their patients and the prevalence of conditions 
encountered. 
 
GPs reported that they might have prescribed the weight loss and pelvic floor 
exercise apps more frequently. Instead, they habitually referred patients to 
dieticians and physiotherapists or to programs and tools already compiled as the 
first line of intervention. None of the GPs except for one had watched, read, or 
received any other app-related content apart from the study intervention. 
Knowledge of HANDI was low, especially that apps were included in some HANDI 
entries. However, upon learning this, they all agreed that HANDI would be a reliable 
evidence-based app repository for GPs in Australia. The main barriers and 
facilitators to app prescription in general practice are shown in Table 10 along with 






Tailored education, face-to-face 
training, and information 
dissemination to increase 
knowledge of prescribable apps 
“it's one message consistent and persistent. So if you've got a list 
that you're confident in, then why are you confident in it, what's 
the message behind and then you get it out as many ways as you 
can because none of us is looking at everything all the time. So if 
there's some way to get it out to the colleges, is there some way 
to get it out of the journals, is there somewhere to put it online 
somewhere that's an authoritative source, is there some way to 
get it out through the universities? Word of mouth is always 
good, influencers, social media…  
 “Coming and meeting us and going through face to face, maybe 
demonstrating some, a bit like the drug reps do” 
 “I mean getting doctors early, so getting them through their 
training programs, getting them as GP registrars and making it 
part of there, I think that's where you're going to really get 
significant change.” 
Meaningful familiarity with apps 
 
“GP's own familiarity with the app, that if you're familiar with it, 
it's going to be much easier to prescribe than something that you 
have just head about or read about. “ 
 “I think certainly the more hands-on you can get, I've done a 
couple or participated in a couple of webinars from the e-mental 
health stuff probably a year or two ago and that helped with my 
awareness of things, but my confidence I don’t think improved 
too much. I think you've got to do them. You've either got to… Use 
it yourself or see it being used or at least be familiar with what it 
looks like.” 
Trustworthy source of vetted 
prescribable apps 
 
“I think having somebody external to narrow down the pool of 
apps and say this is a decent product, then you don’t mind 
recommending them in that way.” 
 “if it's coming from a reliable source like the university and say 
these are the apps we think are good quality apps to recommend, 
then I feel comfortable because there is so much information on 
the internet and app world, we don't know which is good quality 
and which is fake.” 
Integration with existing 
software and workflow 
“I think it would be brilliant to have an app that I could use for 
chronic disease management that actually was integrated, that 
the patients could potentially put data into that will then be 
integrated with my software, that would be fantastic.” 
 “Certainly, would help to have them integrated into our - the fact 
that we've prescribed them, into our software, medical software, 
so that we can just click a button to say recommended whichever 
app.” 
Visual reminder or cue for 
prescribable apps 
“having those pads in front of me made me think about it, the 




 “I think having something like you did that makes it easy to give 
them out, that makes it easier and not having too many, just 
having a few that is quite good.” 
Patients’ capability and attitude 
towards mHealth apps 
“most of the current population, the phone is the one thing that 
they carry around that they have with them all the time. Instead 
of - especially them being able to use it as an extra tool, they're 
useful in the way of treating patients.” 
Proof of benefits of apps as an 
alternative and or adjunct 
treatment 
“sometimes the apps were very useful for patients who I was 
aware weren't able to afford other options. So for example, the 
pelvic floor exercises app would sometimes occur to me when I 
was talking to patients about the difficulties of accessing 
physiotherapy due to the cost and it would then prompt me to 
think, oh yes, actually I have an app that you could try at home 
without cost.” 
 “maybe some data showing that they are received well by 




This study demonstrated that it may be possible to increase the uptake of mHealth 
app prescription by providing an implementation intervention in the Australian 
general practice setting. The results demonstrated a total of 1324 app prescriptions 
by 39 GPs over 4 months and positive feedback from GPs about the intervention. 
The fortnightly number of apps prescribed per GP more than doubled compared to 
the prestudy level. However, identified barriers to app prescription uptake were 
poor knowledge of prescribable apps and insufficient familiarity with the apps to 
foster confident prescribing habits. Participants identified a need for a reliable 
prescribable app repository, preferably integrated with their electronic medical 
systems, and consistent and persistent messaging to increase the knowledge and 
familiarity of such apps.   
The variation in the total individual tally of apps prescribed by participants may 
reflect differences in their personal digital propensity and flexibility in altering 
prescribing behavior. The reduction in the monthly app prescriptions after the first 
month could be related to the timing of the second and third reporting for about half 
of the participants. These occurred during the Christmas, New Year, and summer 
holidays in Australia, during which acute conditions dominate GP visits more than 




The app explanation videos had varying effects on app prescription numbers. The 
results from the qualitative interviews showed that app prescription numbers are 
primarily dependent on the patient cohort and the prevalence of the conditions for 
which the intervention apps were intended. Thus, the short explanatory videos were 
informative but unlikely to be sufficient to influence complex behaviors such as 
prescribing. Perhaps, it would be more beneficial if video introduction and 
instructions for mHealth apps were developed for patients and given as part of the 
app prescription.  
This is the first study to test the feasibility of an intervention to increase app 
prescription in Australian general practice. The overall attrition rate was low, and 
we analyzed the data as ITT, including those who dropped out of the study. 
Limitations include lack of access to electronic medical record data of the GP clinics 
to correlate the prevalence of conditions with the frequency of app prescription 
within the patient cohort. We aimed to recruit a sample of GPs representative of the 
national GP cohort; however, our participants’ median age of 40 years was younger 
than the national average of 50-55 years. Other limitations include a single-group 
pre-post study design, possible volunteer bias of the participants, and short time 
frame (4 months). Ideally, a randomized controlled trial should be conducted to 
establish the long-term effectiveness of the intervention with a large and 
representative sample for a longer duration. Due to the restrictions of available time 
and resources, we were unable to achieve this. Future studies should also opt for an 
electronic version of app prescription to improve sustainability and scalability. 
Another limitation is the analysis of qualitative data by a single researcher; however, 
the qualitative data result was a small part of our secondary outcome to primarily 
answer if the intervention was acceptable and feasible for practicing GPs.  
There are few comparable studies of app recommendation in a primary care setting. 
A trial for an app prescription platform, AppSalut, in Spain involved 32 doctors who 
made 79 app recommendations in 5 months. Of the three apps they used, a 
medication adherence app was the most prescribed [4]. It sends the prescribed app 
to patients as text messages and can monitor and receive data on patients’ use and 
adherence to the system. In the United States, the Cambridge Health Alliance 




program, in which they evaluated mental health apps, selected 7 apps, and 
recommended these 7 apps in 12 primary care clinics [5]. Similar to the finding of 
our study, app prescriptions for anxiety and stress were the most frequently 
prescribed. An Australian study tested the feasibility of integrating mHealth apps 
into dietetic practice by asking 5 dietitians to use one chosen app for 12 weeks [6]. 
All of these studies provided training to the participating health care professionals 
to educate them about the study apps as well as the electronic systems they needed 
to use. The qualitative feedback from our participants also included the need for 
such training. However, because GPs often report being overworked, time-poor, and 
inundated with different information and offers, it would be challenging to organize 
out-of-hours training involving many GPs or train dedicated personnel to visit GP 
clinics during lunch hours, which was suggested by the GPs as a solution. The 
scalability of such an intervention would pose funding and logistical challenges.  
One way to promote the sustainability and scalability of mHealth app integration 
into clinical practice is to provide an electronic repository of vetted and curated 
apps for health care professionals. In Australia, the Victoria Department of Health 
[24], Black Dog Institute [25], and HANDI project by the Royal Australian College of 
General Practitioners [26] offer small repositories of mHealth apps, but these 
organizations function under different jurisdictions with no national guideline in 
place. GPs in our study emphasized the need for a nationally accessible repository 
of a select few prescribable apps that are relevant to general practice that is safe, 
reliable, and easy to navigate.  
We found that mHealth app prescription is feasible in a general practice setting in 
Australia by addressing previously identified practical barriers to mHealth app 
prescription. Our implementation intervention was effective in increasing app 
prescription. However, the future of app prescription depends on efforts to increase 
GPs’ knowledge of prescribable apps as well as a dedicated trustworthy app 
repository for GPs.   
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This chapter summarises the findings and novel contributions of all four studies 
within the broader scope of the overarching thesis aim. It also discusses the 




















7.1 DISCUSSION OF THE MAIN FINDINGS 
The overall aim of this thesis was to evaluate the evidence of effectiveness of patient-
facing stand-alone mHealth apps and to explore the interest and feasibility of 
mHealth app prescription in Australian general practice. This aim was achieved by 
undertaking a series of connected studies: by assessing the evidence of effectiveness 
of mHealth apps (Chapter 3), determining the barriers and facilitators to 
prescribing mHealth apps in Australian general practice (Chapters 4-5), and by 
testing the feasibility of an implementation intervention to overcome the identified 
barriers and increase app prescription by GPs (Chapter 6).  
This thesis provides a window into the body of evidence on currently available 
stand-alone mHealth apps with a special focus on their “prescribability” in general 
practice settings. The focus is here - because that is where effective stand-alone apps 
can be easily integrated into clinical practice and help both patients and doctors. 
However, it is possible for other primary care practitioners, such as diabetes nurses, 
dieticians, and physiotherapists, to prescribe suitable health apps to patients [1]. 
The perspectives of patients and practicing GPs have been invaluable in achieving 
the objectives of the thesis and addressing the barriers to app prescription.  
EVIDENCE OF EFFECTIVENESS OF MHEALTH APPS 
In Chapter 3 (Study 1), the concept of “prescribable” health apps was proposed and 
defined as: currently available, proven effective and preferably stand-alone. Due to 
the high number of available apps in app stores, a systematic review of RCTs of 
prescribable apps was needed. However, a preliminary search revealed several 
systematic reviews of RCTs of apps in specific disease areas and since general 
practice deals with a variety of conditions, it was appropriate to conduct an 
overview of systematic reviews to find relevant apps.  
Study 1 found that a very small percentage of all available apps had been rigorously 
evaluated (Figure 7). From the overview, only 11 trials of apps showed a meaningful, 
yet small to medium effect on health or surrogate outcomes attributable to apps 
were identified (Table 3). However, the overall evidence of effectiveness was 
hampered by pilot studies, small sample size, high risk of bias, and high attrition 




In turn, this hinders the prescribability of those apps. Furthermore, one of the main 
purposes of Study 1 was to identify prescribable apps that can be used to test the 
concept of app prescription in general practice (Study 4) provided that they remain 
available in Australian app stores, and stay stable in terms of content and features. 
Ultimately, we were able to use four apps identified during the conduct of this study 
in our final study. 
Any intervention that claims to improve health should be supported by evidence of 
effectiveness. Rigorous standards of quality and safety must not be relaxed because 
of the allure of technology. Currently, mHealth apps are shown not to be the panacea 
that ‘Silicon Valley’ makes them out to be. Furthermore, one of the main purposes of 
Study 1 was to identify prescribable apps that can be used to test the concept of app 
prescription in general practice (Study 4) provided that they remain available in 
Australian app stores, and stay stable in terms of content and features. Ultimately, 
we were able to use four apps identified during the conduct of this study in our final 
study. 
BARRIERS TO AND FACILITATORS OF PRESCRIBING MHEALTH APPS IN AUSTRALIAN 
GENERAL PRACTICE 
Following the evaluation of the evidence base, two interconnected studies, Studies 
2 and 3 (Chapters 4 and 5), were conducted to explore the barriers to and 
facilitators of mHealth app prescription in Australian general practice. These were - 
an interview study with patients and GPs (Study 2), and a national survey study with 
GPs (Study 3). The interviews with patients and GPs found that mHealth apps 
prescription is perceived as inevitable and achievable. Both patients and GPs are 
aware of and overwhelmed by the sheer number of apps available and identified the 
need for a more trustworthy source of health apps other than the app stores. For 
patients, their GPs represent a trusted source.  
However, the interview analysis showed that  main barriers from the GPs’ 
perspectives were a (1) generational difference in the digital propensity for both the 
GPs and patients; (2) lack of knowledge of prescribable apps and lack of reliable 
source to access apps; (3) the time commitment required of GPs and patients; and 




barriers, the lack of knowledge of prescribable apps and lack of reliable source to 
access them was shown to be the most prominent concern in the survey results 
(Figure 11). This was also the one that could be influenced by implementation 
interventions that were possible within the scope of this thesis. Further comments 
from the participating GPs also hinted at potential solutions to this barrier: a need 
for an education and training on mHealth apps, app prescription skills, and most 
importantly trustworthy source of prescribable apps at their fingertips.  
This barrier of lack of knowledge and resources can be addressed by behaviour 
change interventions. It can be mapped onto the COM-B model for understanding 
behaviour to assist with intervention development [3]. Education, training, 
enablement, and incentivization are the strategies identified by COM-B that can 
provide GPs with the knowledge, skills, and tools to integrate mHealth apps into 
their practice. Lack of education and training is one of the most common barriers 
that HCPs face in adopting new technology in healthcare [4-6] and this study also 
reflects this essential element. Furthermore, the potential to increase HCPs’ time 
strain and workload are common factors of poor uptake of new health technologies 
[7, 8]. However, understanding the value of new technology, such as the potential to 
save consultation time and keep patients engaged and motivated in between 
consultations, can help mitigate against perceived barriers.   
FEASIBILITY OF MHEALTH APP PRESCRIPTION IN AUSTRALIAN GENERAL PRACTICE 
Study 4 tested the feasibility and effectiveness of an implementation intervention 
we developed to overcome one barrier we chose from the preceding studies with an 
aim to increase the uptake of mHealth app prescription in Australian general 
practice (Chapter 6). Due to time and resource constraints of the PhD, we were 
unable to conduct a RCT. Instead we conducted a single group before-after study 
with pre-study survey and post-study interviews. The implementation intervention 
was shown to be highly acceptable and successful in achieveing the study aim of 
increasing uptake of prescribable apps.  
The variation in the total individual tally of apps prescribed by participants was 
wide (Figure 15). This may reflect differences in their personal digital propensity 




the study team’s vetting process and credibility. The app introduction videos 
intended to serve as additional education and training to enable the GPs to develop 
knowledge and familiarity with the apps. However, because only one app video was 
sent to each GP midway through the 4-month study, many GPs did not gain or retain 
much information from them. Also, it would take more detailed information and 
sustained exposure than watching a 2-minute video on one occasion, to develop a 
meaningful familiarity with the apps. For example, the most frequently prescribed 
app Smiling Mind was the most well-known app among GPs and patients alike 
because it has been created and advertised in Australia for a number of years and is 
also used in many Australian schools.  
The feedback interviews conducted at the end of the study revealed insights into the 
intervention and GPs’ prescribing behaviour.  The prescription pads provided a 
visual cue and physical tool, which was found to be important in guiding GPs’ 
prescribing behaviour. The prescription pads seem to be more influential than the 
app introduction videos. The interviews also provided more depth into the barriers 
to app prescription uptake, such as personal familiarity with the apps is likely as 
important as knowing the app’s name and credibility to foster confident prescribing 
habits. It was also suggested that  integrating the much needed repository of 
prescribable apps with the electronic medical systems of GP practices would further 
enhance the adoption of app prescription by reducing friction and streamlining the 
process. 
Changing GPs’ prescribing behaviour is complex [9]. Tailored interventions that 
were developed based on identified barriers to implementation are shown to be 
more effective in changing clinician’s practice [10]. This thesis aimed to achieve that 
by using step-by-step exploration of the barriers to and facilitators of app 
prescription, and successfully developed and tested a tailored implementation 
intervention. Recommendations arising from this thesis and future unanswered 
research questions are discussed later in this chapter.  
7.2 FURTHER PERSPECTIVES ON MHEALTH APPS  
mHealth apps make up a considerably small part of the new technology landscape 




the bigger picture of these technologies and their evolution. Gartner Hype Cycle 
helps us to see that every new technology-based tools that enter healthcare come 
with a big bubble of hype around them, which bursts open upon close scrutiny and 
the real value they may offer to healthcare is then eventuates [11]. At the start of 
this PhD in 2016, mHealth apps were at around the Peak of Inflated Expectations 
(Figure 17). Daily headlines with lists of top apps for many different conditions 
were the norm, but the literature did not reflect that as evidenced by Study 1. 
Then, their popularity slowly declined, and they were mostly replaced by Artificial 
Intelligence (AI) and other new technologies entering healthcare as the new 
“disruptors”. Currently, mHealth apps are undergoing major disillusionment that 
they are not and have never been the panacea we all hope every new technology to 
be. Most mHealth apps fail to demonstrate clear health improvements, we need to 
re-evaluate the design to improve the second- and third-generation apps and to 
enhance testing to improve the relevance, maturity, and benefit of the apps. Only 
then we can hope to ascend onto the Slope of Enlightenment.  
 
 
Figure 17. Gartner Hype Cycle showing relative position of mHealth apps during the conduct 





Furthermore, the new and improved models of smartphones and smartwatches are 
also integrating many health-related functions and sensors such as step-counting, 
sleep tracking, calorie expenditure calculation and mindfulness as native 
smartphone functions. So, the need to download extra apps or buy separate fitness 
trackers are rapidly declining especially in areas of health and fitness. Thus, perhaps 
the main area of impact of mHealth apps will be the Medical category apps, which 
has a significantly smaller market than Health and Fitness yet requires more serious 
level of regulation, making mHealth apps not a very profitable area of health tech, 
but this decline in scope will in turn be favorable to the regulatory opportunities. 
7.3 STRENGTHS AND LIMITATIONS 
The strengths and limitations of the individual studies have been discussed in the 
relevant chapters and are summarised in Table 11. The key strength of this thesis 
lies in its pioneering exploration of mHealth app prescribability in general practice 
and the evidence it contributes to the body of knowledge in the applied mHealth 
research field. The use of rigorous study methodologies, reporting guidelines, and 
risk of bias tools further adds to the strength of the research in this thesis. All four 
studies are published in peer-reviewed open-access journals. 
Another strength is that all of the primary studies were conducted in a ‘real-world’ 
setting and involved practicing GPs in Australia. This was important for helping to 
understand contemporary barriers and facilitators, and to use this understanding to 
develop feasible and acceptable solutions. The studies also achieved an acceptably 
representative sample of participants from all ages, work experience and 
geographical location in Australia through a highly targeted recruitment strategy 
and purposive sampling. Nevertheless, it is still important to recognize the effect of 
selection bias on the results due to the self-selection of participants in the studies. 
Interconnectedness of the studies was also a big strength of this thesis (Figure 2). 
The concept of “prescribable apps” and the mHealth apps that are identified during 
the first study were used in all three subsequent studies. Congruence between 
Studies 2 and 3 - the findings of main barriers to app prescription as determined by 
Australian GPs - ultimately made it possible to design the final study within the 




grounding such as the Theoretical Domains Framework and Behaviour Change 
Wheel to better unify the studies into a gestalt. A particular limitation is that the 
earlier studies lacked a stronger theoretical framework that could have further 
strengthened their findings and subsequently the development of the final 
implementation intervention. 
Table 11. Summary of key strengths and limitations of individual studies in this thesis 





an overview of 
systematic 
reviews 
• Proposed concept of “prescribable” 
apps for general practice setting 
• First study to evaluate the evidence 
behind prescribable apps 
• Broad search strategy and inclusion 
criteria 
• Contacted extensive number of 
authors to obtain missing 
information 
• Robust risk of bias assessment 
• Two researchers conducted 
screening and bias assessment 
• Poor reporting of methodology, 
intervention, and risk of bias 
among included studies  
• Lack of high-quality evidence of 
effectiveness of prescribable apps 
• Lack of comparable overviews 







apps in general 
practice 
• One of the first attempts at an in-
depth exploration of barriers to 
mHealth app prescription in general 
practice 
• Purposive sampling to include all 
ages and GP experience levels 
• Identified and compared barriers to 
app prescription from both GPs and 
patients’ perspectives 
• Small sample size skewed towards 
healthy patient cohort and 
metropolitan GPs 
• Lack of triangulation of data and 
member checking 
• Possible lack of reflexivity 






• National reach  
• Representative sample 
 
• Low response rate 
• Selection bias 







• First study to test the feasibility of 
implementation intervention for 
app prescription in general practice 
• Low attrition 
• ITT analysis 
• Pre-post study design 
• Relatively young GP cohort 
• Selection bias 
• Lack of triangulation of the app 
prescription numbers with the 
prevalence of conditions among 
patient populations 
• Analysis of qualitative data by a 





7.4 RECOMMENDATIONS AND IMPLICATIONS  
This section outlines five recommendations that are being proposed based on the 
findings of this thesis. The first three recommendations focus on improving the 
quality of mHealth app research. The last two recommendations address 
implementation issues, such as creating a national-level evidence-based app 
repository and regulatory framework for mHealth apps for Australia.   
“We need less research, better research, and research done for the right reasons”  
Doug Altman 
When it comes to mHealth app research, the late Doug Altman’s famous words need 
a slight modification [12]. Right now, we need ‘more research’ into the effectiveness 
and safety of mHealth apps to evaluate their potential in improving care and health. 
Chapter 3 (Study 1) identified that a very small proportion of all available apps have 
undergone testing. Most RCTs tested mHealth apps against treatment as usual, but 
the comparator interventions were often multifaceted, therefore hindering the 
interpretation and attribution of treatment effect to the use of apps (Table 3). Simple 
comparative studies of the app version of interventions with the other established 
interventions (such as paper diary, text message reminder, educational pamphlets, 
phone calls, or web-version of the interventions) will produce more practical results.  
Most importantly, trial results should be reported as between-group differences 
[13], which many RCTs did not. The only way to establish the effect of an 
intervention is by demonstrating a greater change in the intervention group 
compared to the comparison group, rather than change from baseline within each 
group.     
1. More pragmatic trials on the comparative effectiveness of mHealth 
apps against other proven interventions and different modalities of 





The studies also should be pragmatic in design so that they can directly answer 
whether the intervention app actually works in real life [14]. Many mHealth apps 
failed to demonstrate the same effectiveness in real-world settings as they did in 
pilot studies or the full explanatory RCTs [15]. Therefore, pragmatic trials conducted 
in the specific environment that the app will be used will increase the rigorousness 
of future studies and their generalizability.  
Chapter 3 (Study 1) also identified several gaps in the quality of research in testing 
and reporting of mHealth apps. Consistent sources of high risk of bias in the RCTs 
were lack of blinding of participants and personnel to the intervention and lack of 
allocation concealment. While blinding can be challenging in mHealth studies, it is 
important because of the digital placebo effect, which could be overcome by using 
sham or ‘placebo’ apps [16].  
The completeness and quality of the reporting of the included systematic reviews 
and RCTs was poor. Many of the RCTs did not include sufficient descriptions of their 
interventions to allow replication, and the availability of their study apps beyond 
the study period was uncertain. Sharing information among researchers working in 
app development and testing is vital to reduce research waste and prevent 
unnecessary duplication. Despite the low number of effectiveness studies, digital 
health interventions are already plagued by a reproducibility crisis [17]. Hence, we 
must promote the importance of providing complete and transparent reporting of 
app interventions, as is true of other interventions in health care. This can be 
achieved by following the guidance provided by TIDieR [18].     
Existing systematic reviews in this area also do not adhere to the PRISMA statement 
[19] in their reporting. Many did not conduct risk of bias assessments of the included 
studies or integrate the risk of bias results into the overall synthesis, thus preventing 
the readers of the reviews from recognising the poor quality of the included studies. 
2. To help improve the quality of evidence of effectiveness of mHealth 
apps, trials of mHealth apps need to improve methods and adhere to 




Risk of bias issues at every level of evidence are compromising the quality of the 
evidence of effectiveness of mHealth apps.  
Findings of Studies 2-4 provide the basis for this recommendation. The GPs who 
participated in these studies expressed the need for a national, accessible, and 
trustworthy repository of selected prescribable apps that are relevant to general 
practice, that is safe, reliable, and easy to navigate. Study 4 used app prescription 
pads printed on paper, akin to traditional prescription pads. The tangible and 
familiar way that the doctors perceive prescription appeared to be the biggest 
appeal of the printed app prescription pads. However, it is not sustainable and 
practical to produce prescription pads for the many different apps that are useful in 
general practice, keep them updated as apps change, and supply them to GPs around 
Australia on an ongoing basis.  
One of the most promising ways to promote the sustainability and scalability of 
mHealth app integration to clinical practice may be to provide an electronic 
repository of apps for GPs. Currently, in Australia, the Victoria Department of Health 
[20], Black Dog Institute [21], and Health Direct consumer web resource [22] offer 
small repositories of mHealth apps. However, none have transparent vetting 
processes and evaluations.  
Studies 2 and 4 also found that the most trusted source of professional and practice-
related information and guidance for GPs is the RACGP. One of the many resources 
that the RACGP provides for GPs is HANDI, which already includes a small number 
of mHealth apps [23]. Upgrading, re-organising, and consistent and prominent 
branding and messaging of HANDI as also containing an app repository may be one 
of the most efficient ways to assist Australian GPs to learn about and potentially use 
and adopt mHealth apps. The RACGP is also well-placed to coordinate the 
 
3. Establishing a repository of trustworthy prescribable mHealth apps for 
GPs is crucial in the uptake of effective mHealth app prescriptions in 
general practice; a national-level professional organisation should take 





opportunities to integrate app repositories with the most common electronic 
medical record software that is used in Australian general practices. 
The RACGP recently released their renewed research priorities [24]. Many items in 
the top 20 priorities offer opportunities to integrate mHealth apps – these include 
consumer focus, mental health, avoiding hospitalisations, use of technology in 
primary care delivery, obesity, health promotion and illness prevention, and non-
pharmacological treatments. There are numerous apps available for the top ten 
most commonly presented medical problems in general practice: hypertension, 
immunisation, upper respiratory tract infection, depression, diabetes, lipid disorder, 
general check-up, osteoarthritis, back complaint, and prescription request [25]. 
Evaluating and including mHealth apps according to such areas of importance 
further improve the usefulness of mHealth app repositories.  
All issues around mHealth app prescription are impacted by the fundamental lack 
of comprehensive app regulation and evaluation in Australia. This is an important 
challenge for Australian digital health governance due to its impact on patient safety 
[26]. mHealth apps regulation requires a multifaceted approach as the existing 
volume of apps and a multitude of stakeholders involved in the development, 
marketing, and consumerisation of apps span a wide variety of jurisdictions [27].  
App store requirements for health and medical apps have never been, and continue 
to not be, sufficiently rigorous. Apple’s introduction of a “physical harm” clause 
under safety requirements in 2016 has been a step forward. It states that “medical 
apps that could provide inaccurate data or information, or that could be used for 
diagnosing or treating patients may be reviewed with greater scrutiny” [28], but the 
who, what, when and how of the “greater scrutiny” is unclear. Google Play currently 
does not have any special requirements for publishing apps in mHealth categories.   
In the US, the Food and Drug Administration (FDA) has decided to regulate mHealth 
apps using a risk-based approach like other medical devices. Apps that satisfy the 
4. The establishment of national mHealth app regulation framework is 





definition of “software as a medical device” and poses a potential risk to human 
health have to go through the FDA approval process [29]. The Federal Trade 
Commission (FTC) keeps the low-risk mHealth apps accountable, which makes up 
the vast majority of apps in the app stores. The FTC also released best practice 
guidance for mobile health app developers that is mainly geared towards data safety, 
privacy and security issues, rather than health safety or efficacy [30].  
In the UK, the NHS Digital offers an app library for patient-facing mHealth apps. It 
outsources the app evaluation to private organisations that specialises in vetting 
mHealth apps, such as the Organisation for the Review of Health Apps (ORCHA) [31], 
before issuing its stamp of approval. ORCHA itself offers a highly searchable large 
repository of vetted apps that contains over 5000 mHealth apps in 24 categories 
evaluated by three main areas: data privacy, clinical assurance, and user experience. 
However, they must comply with the National Institute for Health and Care 
Excellence’s Evidence standards framework for digital health technologies [32].  
In Australia, the Therapeutic Goods Administration takes a similar approach to the 
FDA and regulates medical apps that classify as software as a medical device [33]. 
The Australian Digital Health Agency developed the National Digital Health Strategy, 
but it is not yet involved in the regulation of mHealth apps, their safety, privacy and 
efficacy. A recent report on national digital health safety governance in Australia 
concluded that Australia cannot delay the creation of national digital safety 
measures because patient safety is the ultimate outcome that needs to be achieved 
[34]. This fifth of the thesis is in agreement with the findings and recommendations 
of this report.  
7.5 UNANSWERED QUESTIONS FOR FUTURE RESEARCH 
1. How should we evaluate the prescribability (the effectiveness, safety, and 
usability) of mHealth apps in a sustainable and timely manner?  
To be prescribed, apps should, at the very least, be shown to work and to be safe and 
usable [35]. Safety and usability issues are challenged by the fast-evolving nature of 
the operating systems and commercial aspects of the technology. Pham et al argue 




evaluate fast-evolving technology-based interventions [36]. The challenge of ever-
changing operating systems and app software and funding issues support this 
argument. However, given that Study 1 (Chapter 3) showed that the effect of apps 
as health interventions might be small, marginal benefits can only be reliably 
detected by rigorous testing.  
There are a couple of approaches that can help solve this problem of time-intensive 
traditional way of conducting RCTs. Murray et al suggested that full RCTs should 
only be conducted once the intervention app is stable, can be implemented with high 
fidelity, and there is a reasonable likelihood of clinically meaningful benefit of the 
intervention shown in initial testings [37]. Additionally, the sustainability and 
timeliness of app evaluations can be improved by first conducting a pilot study, 
which includes user feedback to assess potential benefits prior to further 
development and testing [38].  
Another emerging approach is to conduct app RCTs online. Bindhim et al conducted 
an online double-blind RCT of a smoking cessation app. Participants were recruited 
internationally through the app store downloads, which helped save time and 
resources for recruiting compared to traditional in-person approach [39]. They used 
a simpler version of the intervention app as a control, thus mitigating for a potential 
digital placebo effect. Although, online recruitment saves time, it also introduces 
self-selection bias to the study. However, app developers should explore similar 
options and opportunities when testing mHealth apps. 
Timely synthesis of the research in mHealth app effectiveness is highly important 
yet time-intensive, as demonstrated by the conduct and conclusion of Study 1. 
Contemporary approaches to evidence synthesis, such as living systematic reviews 
as suggested by Elliot et al, may be particularly well-suited to keeping up evidence 
syntheses for fast-paced technology-based interventions such as mHealth apps up 
to date [40]. The Clinical Trials Transformation Initiative created a program for 
Mobile Clinical Trials and an online database of feasibility studies for mobile and 
wearable technologies [41]. More initiatives like these are needed to improve the 




2. What are the factors that impact patient adherence rates to prescribed 
mHealth apps?   
This thesis primarily examined the possibility of mHealth app prescription from the 
GPs’ perspective, although Study 2 did interview a small number of patients. Future 
studies should further explore barriers to and facilitators of long term adherence to 
apps from patients’ perspectives because low levels of use after app 
recommendations is a big challenge in digital health [42, 43]. Real-world app 
adherence and engagement levels have been shown to be low: drop out from studies 
can be as high as 80% and sustained use of apps can be as low as 0.5% [44, 45]. Most 
user experience studies show that consumers and patients stop using apps actively 
within a week [46, 47]. The exponential growth of apps since the origin of app stores, 
which were mostly available for free or for a one-off price of less than AUD$3, likely 
contributes to the perception of apps as being low value and dispensable.  
Some of the theories that explain the low adherence to apps are a lack of user-centric 
design and low usability of apps [48]. It is important to involve the end-users 
whether they are pateints or HCPs in every stage of app development, from 
conception, design, testing, through to implementation is important in creating safe, 
effective, and useful apps [49]. An example of a successful solution is the iBobbly 
suicide prevention app, which was designed for indigenous youth of Australia. It 
involved the end-users in every step of the app development and achieved 85% of 
adherence during the trial period [50]. For some apps and settings, HCPs are also 
one group of users and therefore their input into the intricacies of the management 
of specific conditions and health service settings is valuable and needed. 
Accountability and personalised care appear to be important contributors to app 
adherence. A growing number of app studies show that human connection and 
follow-up, in addition to app prescription, increase app adherence. Potentially this 
increased adherence may also be a contributor to improved patient outcomes, 
particularly in mental health and weight loss studies [44, 51, 52]. Therefore, it is 
important to  explore the impact of patient involvement in app development, 
feasibility and effects of different modalities of intervention delivery and follow-up 
(such as face-to-face, telephone, video calls or SMS) on long-term app adherence and 




3. What are the potential or real harms and detriments mHealth apps can cause, 
contribute to, or have caused in real-world?  
Technology use can be a double-edged sword. It is a tool that is inherently neither 
bad nor good. It is what we do with it or how we choose to use that gives it the 
positive or negative attributes. mHealth apps are inseparable part of smartphones 
and other smart devices and thus closely linked with the larger contexts and 
circumstances in which these devices are used. Therefore, harms associated with 
mHealth apps can be categorized as: 
• app-related: incorrect or non-evidence-based content [26], harms arising 
from inaccurate measurement (e.g. blood pressure) [53], lack of timely escalation 
(e.g. worsening depression, exacerbation of eating disorders [54]), false or 
misleading claims of health benefit [55], anxiety associated with constant 
quantification of life, food, sleep, and weight [56], or unintended reverse effects such 
as app designed for moderating alcohol use instead increasing alcohol intake[57].   
• smartphone and its wider use related mental, physical and social effects: 
smartphone or app addiction [58], data breach [59], loss of privacy [60, 61], financial 
scamming (e.g. making it hard to unsubscribe from the service) will all erode trust, 
and hinder adoption of technology and adherence to beneficial digital interventions.  
These harms need to be studied and measured for us to understand consumer usage 
and behaviour, and to develop safer apps and better evaluation and regulatory 
frameworks.  
4. What is the effectiveness of mHealth apps with additional personal support and what 
are the feasibility and cost-effectiveness of implementing them primary care compared 
to stand-alone apps?  
The primary focus of this thesis was the effectiveness of stand-alone mHealth apps. 
However, mHealth apps that are ‘not stand-alone’ and designed to be used in 
conjunction with support from HCPs, health coaches or even chatbots are a major 
part of the mHealth app world and there are some evidence to show that they 
perform better than stand-alone apps [51]. The additional supports can be 
personalised goal setting, real-time or regular feedbacks, and individualised 
communication provided through built-in app features or add-on services such as 




in-between the consultations. Such additions could make mHealth app 
implementation into clinical practice more resource-intensive and costlier than 
stand-alone options, but how exactly these apps compare with stand-alone apps and 
what the effective “doses” for each support are also priority research questions in 
digital health. 
7.6 CONCLUSION 
The research in this thesis evaluated the evidence of effectiveness of patient-facing 
stand-alone mHealth apps and explored the feasibility of prescribing them as a non-
drug intervention in general practice. From an overview of systematic reviews, it 
was concluded that the evidence of effectiveness for mHealth apps is emerging. 
From the interviews with patients and GPs and survey of GPs, it was found that both 
groups accept that app prescription is possible, inevitable, and acceptable, although 
GPs are currently not sufficiently knowledgeable or resourced to optimally 
prescribe apps. The future of app prescription in Australian general practice 
appears to be likely influenced by efforts to increase GPs’ knowledge of prescribable 
apps as well the creation and maintenance of a dedicated app repository for GPs.  
It is a challenge for 21st-century HCPs to keep up with the soaring number of 
mHealth apps, which are also of variable quality. The research in this thesis had the 
underlying philosophy of desiring HCPs to be able to use these new tools in their 
clinical practice with a positive impact on patients. To safeguard patient safety, as 
HCPs, and researchers, we must drive the push to ensure that the potential of this 
new technology is evaluated rigorously and harnessed without inappropriate hype. 
The sustained involvement of stakeholders in consumer mobile technology, HCPs, 
patients, and policymakers will be vital in the successful integration of mHealth apps 
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